header logo image


Page 743«..1020..742743744745..750760..»

Gene Therapies Make it to Clinical Trials – Discover Magazine

January 1st, 2020 7:45 pm

After years of ethical debates and breakthroughs in the lab, CRISPR has finally made its way to clinical trials. Researchers are now looking at whether the DNA-editing tool, as well as more conventional gene therapies, can effectively treat a wide array of heritable disorders and even cancers.

Theres been a convergence of the science getting better, the manufacturing getting much better, and money being available for these kinds of studies, says Cynthia Dunbar, a senior investigator at the National Heart, Lung, and Blood Institute. Its truly come of age.

CRISPR formally known as CRISPR-Cas9 has been touted as an improvement over conventional gene therapy because of its potential precision. CRISPR (clustered regularly interspaced short palindromic repeats) is a genetic code that, contained in a strand of RNA and paired with the enzyme Cas9, acts like molecular scissors that can target and snip out specific genes. Add a template for a healthy gene, and CRISPRs cut can allow the cell to replace a defective gene with a healthy one.

In April, scientists at the University of Pennsylvania announced they had begun using CRISPR for cancer treatments. The first two patients one with multiple myeloma, the other with sarcoma had cells from their immune systems removed. Researchers used CRISPR to genetically edit the cells in the lab, and then returned them back into their bodies.

On the other side of the country, Mark Walters, a blood and bone marrow transplant specialist at the University of California, San Francisco, Benioff Childrens Hospital in Oakland, is gearing up for trials that will use CRISPR to repair the defective gene that causes sickle cell disease. With CRISPR, once youve made that type of correction, [that cell] is 100 percent healthy, says Walters.

Another team is tackling the same disease using a type of hemoglobin, a protein in red blood cells, thats normally made only in fetuses and newborn babies. Researchers found that some adults continue to produce these proteins throughout their lives, and when those adults also have sickle cell disease, their symptoms are mild. So the international team used CRISPR to disable the gene that interferes with production of this hemoglobin, resuming its production and protecting the adult patients against sickle cell disease.

Several other CRISPR studies are in the works to treat a range of inherited disorders, including hemophilia and SCID-X1 (also known as X-linked severe combined immunodeficiency, the so-called bubble boy disease in which babies are born without a functioning immune system).

At St. Jude Childrens Research Hospital, a gene therapy trial cured Gael Jesus Pino Alva (pictured with his mother, Giannina) of SCID-X1, the bubble boy disease. (Credit: St. Jude Children's Research Hospital/Peter Barta)

The past year also saw success in a handful of experiments on conventional gene therapy. Instead of using CRISPR to repair disease-causing genes, these treatments use hollowed-out viruses to ferry healthy versions of genes into cells. Millions of these altered cells are released into the bloodstream or bone marrow in hopes that enough will land in the right places. But because scientists cant predict where the circulating genes may end up, this shotgun approach has had unintended, sometimes fatal, consequences including, in an earlier study, inadvertently activating leukemia-causing genes in patients treated for SCID-X1.

But in 2019, researchers learned that using a different type of virus one related to HIV to transport the genes may prevent these side effects. In an April study, researchers at St. Jude Childrens Research Hospital in Memphis, Tennessee, and UCSF Benioff Childrens Hospital in Oakland collected bone marrow from eight newborns with SCID-X1. They loaded corrective genes into the disabled HIV-related virus, which carried them into the patients bone marrow stem cells. The infants also received low doses of busulfan, a chemotherapy that gave the doctored stem cells room to grow. So far, we havent seen anything worrisome, says Ewelina Mamcarz, a pediatric oncologist at St. Jude who led the research team. The study recently added its 12th patient.

Gene therapy does have its momentum [back], says Mamcarz, reflecting on the fields setback after the earlier studys leukemia side effects. Theres so much that still needs to be done, and so many questions, she says. [But] this is how medicine evolves. We always want to be better than we were a week ago.

In the future, the hope is that gene therapy technologies will move beyond mending simple genetic mistakes and be used to combat big killers like diabetes or heart disease. [Those diseases are] more challenging, but a lot of them would benefit from knocking out a bad gene, says Dunbar.

For now, though, researchers are optimistic about the progress thats already been made. All of this has been very encouraging, says Dunbar. [And] for sickle cell in the U.S. and hemophilia in the developed world, these diseases may soon be solved.

[This story originally appeared in print as "Gene Therapy Gets Clinical."]

Originally posted here:
Gene Therapies Make it to Clinical Trials - Discover Magazine

Read More...

Deficiency of TRPM2 leads to embryonic neurogenesis defects in hyperthermia – Science Advances

January 1st, 2020 7:45 pm

INTRODUCTION

The cerebral cortex is the most evolved and complicated structure in the mammalian brain and has many physiological functions, such as attention, cognition, learning, and memory. The functions rely on the detailed cortex structure, which includes a six-layered architecture formed by migrating neurons in an inside-out pattern (1). These plentiful neurons are generated from various neural progenitor cells (NPCs). The primary progenitor cells are radial glial (RG) cells, which are mainly responsible for self-renewal and result in the expansion of the cortex, the differentiation of neurons, and the production of postmitotic neurons (2). The process of neuronal production, also known as neurogenesis, plays crucial roles in cerebral development and can affect the function of the neocortex. Generally, each process in neurogenesis, including self-renewal, differentiation, and the maturation of neurons, is strictly regulated, and any disturbance leads to severe disorders (3). The entire process is regulated by numerous extracellular and intracellular signals and factors. Any stress or unusual stimulus may lead to abnormalities in brain function.

During pregnancy, various stimuli can lead to abnormal neural development (4, 5). Among them, heat stress is an important stimulus for both the mother and fetus during pregnancy, and maternal thermal homeostasis is critical for fetal survival and ontogenesis. For example, maternal fever during the gestation period is associated with congenital heart defects and neural tube defects (6, 7). However, it is largely unknown whether heat stress, such as hyperthermia, disturbs neurogenesis and cortical development.

A series of thermally activated ion channels has been reported to detect the entire thermal range (8, 9). Among them, transient receptor potential channel M2 (TRPM2) is a plasma membrane calcium-permeable cation channel and is a unique member of the TRP family that is sensitive to various signals. Recently, studies have reported that TRPM2 can be activated by heat and that the deletion of TRPM2 in mice results in a remarkable deficit in their perception of nonpainful warm stimuli in the range of 33 to 38C (10). TRPM2 has been implicated in several neurodevelopmental/neurological disorders including bipolar disorder, neuropathic pain, and Parkinsons disease (11). In addition, TRPM2 has been shown to participate in various biological processes, including insulin secretion, H2O2-induced cell apoptosis, and brain damage following ischemic insults in adult and neonatal mice (1214). Therefore, it is crucial to investigate the precise functions and molecular mechanisms of the hyperthermia-related protein TRPM2 and characterize the proteins role in the regulation of brain development during heat stress and maternal hyperthermia.

Several pieces of evidence have demonstrated that canonical Wnt signaling, including -catenin, which acts as a core downstream effector, determines the transition from neuronal proliferation to differentiation during cortical neurogenesis. In the early stages of neurogenesis, the overexpression of -catenin in NPCs promotes their proliferation, whereas a deficiency in -catenin in NPCs facilitates neurogenesis (15). The precise signal transductions that modulate neurogenesis are unclear and need further elucidation. The transcription factor SP5 (specificity protein 5) is a member of the SP transcription factor family (16), and previous studies have shown that SP5 plays a crucial role in governing mouse embryonic stem cell pluripotency (17) and neural crest specification (18). During vertebrate development, SP5 acts downstream of Wnt/-catenin signaling in neuroectoderm patterning (19). In addition, the hypermethylation of SP5 has been implicated in schizophrenia, a neuropsychiatric disorder associated with the dysregulation of neural stem cell (NSC) proliferation and differentiation (20, 21). However, the role of SP5 in hyperthermia during neurogenesis has never been reported.

Here, we demonstrate that the thermo-sensor protein TRPM2 is enriched in the embryonic cerebral cortex and that its expression gradually increases during heat stress. We also show that TRPM2-deficient mice exposed to heat show reduced NSC proliferation and a premature shift in RG differentiation. Mechanistically, this study identifies an important role of TRPM2 in modulating SP5 expression by inhibiting the phosphorylation of -catenin in sustaining neural progenitor self-renewal during heat stress. In addition, the heat-induced proliferation defects caused by TRPM2 knockdown or knockout can be partially rescued by the overexpression of SP5. Collectively, these findings reveal that the heat sensor protein TRPM2 has a previously unidentified role in modulating cortical neurogenesis during hyperthermia conditions. These findings provide previously unknown insights to further elucidate neurological disorders associated with heat stress and reveal previously unidentified strategies for treatment.

To determine the effect of heat stress on the developing cortex, we performed stress experiments in which pregnant mice were placed in a thermostatic biochemical incubator (fig. S1A) set to 38C for 2 hours from embryonic day 13.5 (E13.5) to E15.5; the control group was kept at room temperature. After heat stress, E15.5 brain slices were stained with an antibody against mitotic index PH3. Compared with that in the control group, the number of PH3-positive cells residing at both the apical and basal positions was notably augmented, indicating that heat stress promoted mitotic activity (Fig. 1, A to C). Consistently, double staining for bromodeoxyuridine (BrdU) with PAX6 (one type of neural progenitor marker) (Fig. 1, D and E) and TBR2 (an intermediate progenitor marker) (Fig. 1, F and G) revealed that the number of cells in the proliferative state was increased in hyperthermia. Collectively, these results indicate that heat stress promotes neural progenitor self-renewal. In a second group of pregnant mice, similar heat stress was induced at E13.5 to E16.5; then, in utero electroporation (IUE) was performed to analyze embryonic brain development. When embryos were electroporated with a green fluorescent protein (GFP)encoding plasmid, which was used as a control plasmid on E13.5 and collected on E16.5, the hyperthermia group showed an abnormal distribution, which manifested as an increase in the number of cells in the ventricular zone/subventricular zone (VZ/SVZ) and a reduction in the number of GFP-positive cells in the cortical plate (CP) compared with those in the room temperature group (Fig. 1, H and I). In our research, the control mice were maintained in the vivarium at room temperature. We also conducted IUE experiments when mice were maintained in an incubator or in the vivarium at room temperature and found that the stress experienced by the mother due to moving to a new environment did not play a role in the observed phenotypes (fig. S1, B and C). Together, these results demonstrate that heat stress may disturb neurogenesis during embryonic brain development.

(A to C) E15.5 brain sections from the room temperature and hyperthermia groups were immunolabeled with the mitotic marker PH3 and 4,6-diamidino-2-phenylindole (DAPI). The graphs show the number of PH3+cells per 100 m2 at the apical and basal positions (n = 6). Scale bar, 20 m. (D to G) Mice underwent 2 hours of BrdU pulse labeling and were euthanized at E15.5. Brain slices were then double stained with antibodies against BrdU/PAX6 and BrdU/TBR2. The graphs show the populations of BrdU+PAX6+ and BrdU+TBR2+ cells relative to the total population of BrdU+ cells (n = 6). Scale bars, 20 m. (H and I) Thermal stimuli lead to the abnormal distribution of GFP-positive cells in the developing neocortex. An electroporation experiment was conducted at E13.5, and embryonic brains were collected on E16.5. The percentage of GFP-positive cells in each region is displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. IZ, intermediate zone. (J) Reverse transcription polymerase chain reaction (RT-PCR) results showing the relative mRNA levels of members of the TRP family in the heat stress experiment (n = 3). n.s., not significant. (K) TRPM2 is abundantly enriched in NESTIN-positive NSCs in the embryonic cerebral cortex. E13.5 and E15.5 brain slices were immunostained with anti-NESTIN and anti-TRPM2 antibodies (VZ/SVZ) (n = 5). Scale bars, 20 m. (L) TRPM2 is expressed and colocalized with SOX2 and NESTIN in primary NSCs. The cells were collected from the cerebral cortex of E12.5 mouse brains and maintained in proliferative medium for 24 hours (n = 4). Scale bars, 20 m. (M and N) TRPM2 expression increases at warm temperatures in the E15.5 cerebral cortex. E15.5 brain sections were stained with an antibody against TRPM2. The graph shows the relative expression intensities of TRPM2 (n = 6). The intensity of TRPM2 was quantified with ImageJ. Scale bar, 20 m. The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

It has been reported that many receptors are thermally sensitive (10). To verify heat sensitivity, we housed pregnant mice with E13.5 fetuses at 38C for 2 hours for 3 days. Control pregnant mice were kept at room temperature. After 3 days (i.e., E15.5), RNA was extracted from the cerebral tissues of fetal mice. We detected the RNA levels of several receptors associated with heat (10, 22) and observed that in mice subjected to heat stress, the mRNA levels of only TRPM2, among the numbers of the TRP family, increased significantly (Fig. 1J). Molecular markers of heat-sensitive neurons within the preoptic hypothalamus were also affected. BDNF and PACAP mRNA levels increased (fig. S1D), which is consistent with previous studies (23). To examine the specific expression pattern of TRPM2 in the early embryonic brain, we conducted immunofluorescence and colocalization analyses. In vivo, the brain sections of E13.5 and E15.5 mice were collected and stained with antibodies against TRPM2 and the two neural progenitor markers, namely, NESTIN (24) and SOX2 (sex-determining region Yrelated HMG box 2). TRPM2 was observed to be colocalized with NESTIN-positive and SOX2-positive progenitor cells and resided in the VZ/SVZ of the cerebral cortex in both E13.5 and E15.5 brain sections from mice housed at room temperature (Fig. 1K and fig. S1E). In addition, in vitro, we observed that TRPM2 was coexpressed with NESTIN and SOX2 in primary mouse NSCs derived from E12.5 cerebral tissues and cultured in proliferation medium for 2 days (Fig. 1L). Next, to investigate TRPM2 expression at different developmental stages, we harvested cerebral tissues from E13.5, E15.5, and E18.5 and analyzed them using Western blotting. The results revealed that TRPM2 expression gradually increased from E13.5 to E18.5 (fig. S1, F and G). We also investigated TRPM2 transcription in vivo using cortical tissues and in vitro using NPCs cultured under differential or proliferative conditions. Reverse transcription polymerase chain reaction (RT-PCR) was performed on RNA extracted from the tissues or the NPCs. All data indicated that the mRNA levels of TRPM2 showed an obvious up-regulation as embryonic development proceeded (fig. S1, H to J). In addition, another group of pregnant mice was housed at 38C for 2 hours for 3 days at E15.5. Heat-treated mice showed a marked augmentation of TRPM2 expression in the VZ/SVZ of the neocortex compared with that in control mice (Fig. 1, M and N). Overall, these findings suggest that TRPM2, especially during heat stress, plays an important role in modulating NSC neurogenesis during embryonic cortical development.

On the basis of the distinctive expression pattern of TRPM2 in NSCs, we explored whether TRPM2 plays a unique role in neurogenesis during embryonic brain development. We generated a TRPM2-targeting short hairpin RNA (shRNA) plasmid and a TRPM2-overexpressing lentiviral-based vector to effectively silence and augment TRPM2 expression, respectively, in neural progenitors. In NPCs (Fig. 2, A and B, and fig. S1M), N2A cells (fig. S1, L and O), and 293FT cells (fig. S1N) treated with our constructs, Western blotting confirmed TRPM2 knockdown or overexpression. To verify our strategy, we further confirmed TRPM2 shRNA knockdown efficiency by real-time PCR analysis in NSCs, and the analysis showed that TRPM2 levels were effectively suppressed (fig. S1K). Next, we investigated whether TRPM2 disturbs cell distribution in vivo using IUE. In E13.5 mice, brains were injected and electroporated with the TRPM2 shRNA or control plasmid, and the mice were sacrificed at E16.5 for phenotypic analysis. We observed no obvious change in the distribution of GFP-positive cells across the cerebral cortex (fig. S2, A and B). However, the more interesting observation was that when maternal mice were placed in a 38C temperature-controlled incubator for 2 hours from E14.5 to E16.5, TRPM2 knockdown resulted in an obvious reduction in the number of GFP-positive cells in the VZ/SVZ and a corresponding increase in the number of GFP-positive cells in the CP (Fig. 2, C and D). When a 39C temperature-controlled incubator was used, similar results were obtained (fig. S2, C and D). To observe more long-term effects, we performed IUE at E13.5 to E17.5 and comparable GFP-positive cell distributions were observed (fig. S2, E and F). In addition, we also sought to determine whether the knockdown of TRPM2 has a possible effect on cell migration. IUE experiments are frequently used to monitor cell migration during embryonic cerebral development (2527). Then, we performed an E15.5-to-E19.5 IUE experiment in mice at room temperature and an E14.5-to-E18.5 IUE experiment in mice exposed to heat (fig. S2, G to I) and found that there was nearly no difference in GFP distribution from the VZ/SVZ to the CP between the control and TRPM2 knockdown groups. These results jointly eliminated the influence of TRPM2 depletion on cell migration. Thus, the data suggest that TRPM2 may take part in regulating neurogenesis during heat stress.

(A) Western blot analysis confirmed the knockdown (empty pSicoR shRNA was used as a control) of TRPM2 in cultured NSCs. -Actin was used as a control. (B) The graph shows that TRPM2 expression levels were effectively knocked down in primary NSCs by TRPM2-shRNA (n = 6). (C and D) TRPM2 knockdown alters the distribution of cells in the cerebral cortex during heat stress. A control or TRPM2 shRNA plasmids were microinjected and electroporated into the brains of E13.5 mice, and brains were collected on E16.5. During the process, the mice were exposed to 38C for 2 hours per day from E14.5 to E16.5. The GFP-positive cell populations in each region are displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (E and F) The number of TUJ1+GFP+ cells is augmented in TRPM2 shRNAtreated animals subjected to heat stress. Brain slices from E16.5 mice were stained with an antibody against TUJ1. The population of TUJ1+GFP+ cells relative to the total population of GFP+ cells is shown in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (G and H) The number of MAP2+GFP+ cells is slightly increased in TRPM2 shRNAtreated animals in hyperthermia. E16.5 brain slices were stained with an anti-MAP2 antibody. The population of MAP2+GFP+ cells relative to the total population of GFP+ cells is shown in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (I) Silencing TRPM2 induces NPC terminal mitosis during heat stress. A TRPM2 shRNA or control plasmid was injected and electroporated into E13.5 mouse brains. BrdU was gently injected 24 hours after electroporation at E14.5, and the electroporated brains of the embryos were collected for analysis at E18.5. Immunohistochemical analysis was performed using anti-BrdU and anti-CUX1 antibodies. During the process, the mice were exposed to 38C for 2 hours per day from E14.5 to E18.5. The arrowheads represent BrdU+/GFP+ cells, and the arrows represent GFP+BrdU+CUX1+ cells. Scale bar, 20 m. (J) Bar graph displaying the population of BrdU+GFP+ cells relative to the total number of GFP-positive cells in the CP (n = 6 embryos from four different mothers). (K) Quantification of the population of GFP+BrdU+CUX1+ cells relative to the population of GFP+BrdU+ cells (n = 6 embryos from four different mothers). The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

On the basis of the reduction in the number of GFP-positive cells in the VZ/SVZ, which enriches NPCs, we considered the possibility that TRPM2 plays a vital role in modulating NSC proliferation in hyperthermia. To address this possibility, we injected BrdU into pregnant mice 2 hours before the collection of electroporated embryonic brains. In TRPM2 knockdown mice, heat stress at E13.5 to E16.5 led to a marked reduction in the percentage of GFP+BrdU+ cells (fig. S3, A to C), the percentage of GFP+BrdU+PAX6+ cells (fig. S3, D and E), the expression of mitotic marker PH3 (fig. S3, F and G), and the expression of TBR2 (fig. S3, H and I) in NPCs residing in the VZ/SVZ.

Together, these results indicate that TRPM2 is vital for maintaining the NSC pool. To further explore whether a decrease in NPC proliferation leads to precocious cortical neurogenesis, we analyzed cell cycle exit. After electroporating control or TRPM2-shRNA plasmids into embryonic brains at E13.5, BrdU was injected 24 hours before the collection of electroporated brains from embryos on E15.5 and from E14.5 to E16.5. During the process, the pregnant mice were kept at 38C for 2 hours per day. Next, we stained brain slices with antibodies against BrdU and the proliferative marker KI67 to evaluate cells that precociously exit the cell cycle. We observed a substantial augmentation of the indicator of cell cycle exit in the TRPM2-silenced group that was subjected to heat stress, confirming that the elimination of TRPM2 facilitated cell cycle exit in response to hyperthermia (fig. S4, A to C).

To verify the possibility that TRPM2 knockdown NPCs that exit the cell cycle during heat stress may differentiate prematurely into neurons, we stained brain sections with an antibody against TUJ1 (-III-tubulin, a neuronal marker) to label neurons. Analysis revealed an obvious change in the percentage of TUJ1+/GFP+ cells in brain slices from TRPM2 knockdown mice subjected to heat stress (Fig. 2, E and F). We also observed a remarkable increase in the number of cells expressing the neuronal or upper layer markers MAP2+/GFP+ (Fig. 2, G and H), SATB2+/GFP+ (fig. S4, D and E), and CUX1+/GFP+ (fig. S4, F and G) and a decrease in the number of cells expressing CTIP2 (a marker of deep layer neurons)+/GFP+ (fig. S4, I and J) compared to those in control brain slices, suggesting an increase in the differentiation of NSCs. We also birthdated neurons using BrdU to investigate whether TRPM2 knockdown accelerates the terminal mitosis of premature neural progenitors in mice challenged with heat. As previously described (28), BrdU was injected into the abdominal cavity of pregnant mice 24 hours after the electroporation of E14.5 fetuses, and the electroporated brains of the embryos were collected for analyses at E18.5 (fig. S4H). Because BrdU labels dividing cells in the S phase (29), the label becomes diluted and gradually disappeared upon the self-renewal of NPCs. Only cells that differentiate into neurons within the CP layer during their final mitotic division are permanently labeled. By staining with an antibody against BrdU, we observed a marked increase in the number of BrdU+/GFP+ (Fig. 2, I and J) cells in the TRPM2 shRNAtreated brains compared with control shRNAtreated brains. When colocalized with the outer cortical layer marker CUX1, a significant change in the percentage of CUX1+GFP+BrdU+ cells relative to that of GFP+BrdU+ cells in the TRPM2 shRNAtreated group was observed. These results indicate that more BrdU-labeled NPCs differentiated into CUX1-positive neurons in the CP in the TRPM2 shRNAtreated group (Fig. 2K). Collectively, these findings effectively demonstrate that during heat stress, TRPM2 loss of function results in augmented terminal mitosis and enhanced cortical neuronal differentiation.

To verify the role of TRPM2 in neuron development under conditions of heat, we conducted an in vitro experiment using cultured primary NSCs. NPCs obtained from the E12.5 cerebral cortex were infected with either a control or TRPM2 shRNA plasmidpackaged lentivirus. After 24 hours, the cells were then incubated at 38C for 3 days in proliferative medium and finally stained with antibodies against TUJ1 and KI67. We observed an obvious increase in the number of GFP+TUJ1+ cells (fig. S5, A and B) and a marked decrease in the number of GFP+KI67 + cells (fig. S5, C and D) in TRPM2-deficient cells compared with control cells, supporting our in vivo findings. However, when NPCs were incubated at 37C for 3 days, we observed no obvious change in the percentage of GFP+TUJ1+ cells in the TRPM2-deficient cells (fig. S6, H and I).

To further investigate the effects of TRPM2 on NPC morphology during heat stress, we kept NSCs acquired from E12.5 brains in differentiation medium at 38C for 3 days. Using confocal imaging, we observed that compared with control NSCs, TRPM2 knockdown NSCs exhibited longer neurite outgrowth and increased branching after hyperthermia (fig. S5, H to J).

In addition, IUE was performed at E13.5, and the GFP-positive region of the brains from the embryo was collected and digested 2 days after electroporation at E15.5. During E14.5 to E15.5, the pregnant mothers were held at 38C for 2 hours per day. Embryonic GFP-positive brain cells were acquired using fluorescence-activated cell sorting and then cultured for 2 days in proliferative medium at 38C. Notably, TRPM2-silenced cells obtained from embryos whose mothers were heat-challenged showed prominent branching and longer neurite outgrowth compared with empty vectortreated cells (fig. S5, E to G). Jointly, these results suggest that TRPM2 can inhibit neuronal development during heat stress and is required for maintaining stem cell self-renewal.

In E13.5 mice electroporated with a TRPM2 overexpression vector, we observed a prominent increase in the number of GFP-positive cells residing in the VZ/SVZ and a corresponding decrease in the number of GFP-positive cells in the CP at E16.5 when pregnant mothers were subjected to heat stress for 2 hours from E14.5 to E16.5 (fig. S6, A and B). Compared to the normal expression of TRPM2, TRPM2 overexpression during heat stress also led to more BrdU-positive cells in the VZ/SVZ (fig. S6, C to E), supporting a role for TRPM2 in promoting NSC proliferation. In addition, TRPM2 overexpression was found to rescue abnormal NPC distribution caused by the depletion of TRPM2 in vivo (fig. S6, F and G), demonstrating that TRPM2 is required for the proliferation of NPCs during heat stress.

To further explore the phenotype of TRPM2 knockout mice, we generated mice using the CRISPR-Cas9 system through zygote microinjection. The coding sequence (CDS) of TRPM2 is located in exon 3, but not exon 1. After CRISPR editing, a termination codon was introduced near the start codon in the CDS (Fig. 3A). Genotyping PCR (Fig. 3B), Western blotting (fig. S7A), and real-time PCR (fig. S7B) were all performed to identify the knockout efficiency at the genome, protein, and RNA levels, respectively. We verified the knockout of TRPM2 in pregnant TRPM2 knockout mice exposed to hyperthermia at E14.5 to E16.5 by immunostaining E16.5 brain slices with an antibody against TRPM2 (fig. S7C). In addition, by immunostaining with an antibody against cleaved caspase-3, we observed that, in hyperthermia, there was no significant difference in the number of cleaved caspase-3+ cells per field between E16.5 TRPM2+/+ and TRPM2/ brain slices, suggesting that TRPM2 knockout had no effect on cell apoptosis under conditions of heat (fig. S7, D and E).

(A) Schematic diagram of the generation of TRPM2 knockout mice. (B) Genotyping of TRPM2+/+ and TRPM2/ mice. The results show that the PCR products of TRPM2+/+ and TRPM2/ were 1291 and 511 base pairs (bp), respectively. WT, wild type. (C and G) E16.5 brain slices from TRPM2+/+ and TRPM2/ mice were stained with DAPI and an antibody against PH3. Heat stress was applied from E14.5 to E16.5. The graph shows the number of PH3-positive cells per 100 m2 in the VZ/SVZ (n = 6). Scale bar, 20 m. (D and H) TRPM2+/+ and TRPM2/ mice underwent 2 hours of BrdU pulse labeling and were sacrificed at E16.5. Brain slices were then stained with antibodies against BrdU and PAX6. The graph shows the number of BrdU+PAX6+ cells per 100 m2 in the VZ/SVZ (n = 6). Scale bar, 20 m. (E and I) Coronal brain slices of E16.5 TRPM2+/+ and TRPM2/ mice were immunostained with an anti-CUX1 antibody. The number of CUX1+ cells per 100 m2 of CP is shown (n = 6). Scale bar, 20 m. (F and J) Representative images of E16.5 cortices showing SATB2-labeled cells. The graph shows the thickness of SATB2+ cells in the upper layer of the CP (n = 6). Scale bar, 20 m. (K) Deletion of TRPM2 leads to abnormal cell distribution and neurogenesis defects during heat stress. Furthermore, these defects were rescued by the constitutive expression of TRPM2 in the developing brain. A GFP-expressing control vector or TRPM2 overexpression vector was microinjected and electroporated into E13.5 mouse brains. Heat stress was administered from E14.5 to E16.5 for 2 hours a day. The brains were collected on E16.5 and stained for TUJ1. (L) The population of GFP-positive cells in each region is displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. (M) The population of TUJ1+ GFP+ cells among GFP+ cells is displayed in the bar graph (n = 6 embryos from four different mothers). Scale bar, 50 m. The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

Next, we obtained E16.5 TRPM2+/+ or TRPM2/ embryonic brains from mothers that had been housed at 38C for 2 hours per day from E14.5 to E16.5. By staining analysis, we observed fewer neural progenitors expressing PH3 (Fig. 3, C and G) and BrdU/PAX6 (Fig. 3, D and H) in the VZ/SVZ and more neurons expressing CUX1 (Fig. 3, E and I) and SATB2 (Fig. 3, F and J) in the CP in TRPM2 knockout brain slices. In addition, when immunostaining for TRPM2 together with NESTIN or TUJ1 was performed on E16.5, we found that the expression of NESTIN was decreased, while the level of TUJ1 was observably augmented after the deletion of TRPM2 in hyperthermia (fig. S7, F and G). Consistently, when mice were housed at 38C for 2 hours per day from E14.5 to E18.5, more neurons expressing CUX1 were observed in the CP in TRPM2 knockout brain slices both on postnatal day 0 (P0) and P6 (fig. S8, F to I), which suggests that the heat-mediated shift in the proliferation to differentiation ratio upon TRPM2 knockout has a consistent and longer-term effect in later stages of development. However, in brain slices obtained from embryos of mothers who had been housed at room temperature, we did not find an obvious difference in TUJ1 staining at P0 between the wild-type and TRPM2 knockout groups (fig. S8J). Consistently, progenitors isolated from hyperthermic E12.5 TRPM2/ embryos developed longer neurites and more branching after culture in differentiation medium for 3 days than those of hyperthermic E12.5 TRPM2+/+embryos, while room temperature embryos lacked these phenotypes (fig. S8, A to E). These observations suggest that TRPM2 knockout and hyperthermia accelerate neuron development. In addition, NSCs obtained from E12.5 TRPM2/ embryos formed smaller neurospheres than those of controls in hyperthermia, but not room temperature conditions, suggesting that the loss of TRPM2 inhibits NPC proliferation during hyperthermia (fig. S7, K to M). To validate the function of TRPM2 during cortical neurogenesis in times of hyperthermia, we electroporated the brains of fetal TRPM2+/+ and TRPM2 / mice with control plasmids and brains of fetal TRPM2 / mice with TRPM2 overexpression plasmids on E13.5. Then, on E16.5, we collected brain samples from mice that had been exposed to heat stress for 2 hours from E14.5 to E16.5. By staining with an anti-TUJ1 antibody, we found that TRPM2/ mice not only exhibited an aberrant distribution of GFP-positive cells in three cortical layers but also showed a prominent increase in the proportion of GFP and TUJ1double positive cells compared with that in TRPM2+/+ mice, which is reminiscent of TRPM2 knockdown mice subjected to heat stress. Moreover, forced expression of TRPM2 in TRPM2/ mice in hyperthermia could rescue the abnormalities evoked by the ablation of TRPM2, i.e., both the distribution and ratio of GFP+ TUJ1+ cells (Fig. 3, K to M). In addition, we also compared the distribution and ratio of GFP+ TUJ1+ cells between TRPM2/ mice at room temperature and TRPM2/ mice in hyperthermia groups. The results revealed that, upon exposure to hyperthermia, TRPM2/ mice displayed a significant increase in the number of GFP-positive cells in the CP and the percentage of TUJ1+GFP+ cells (fig. S7, H to J). These findings demonstrate the vital role of TRPM2 during embryonic neurogenesis. In addition, the consistent phenotype of TRPM2 knockout excludes the possibility of potential off-target effects of TRPM2 shRNA in knockdown experiments. To investigate the effect of TRPM2 deficiency on differentiating neurons in hyperthermia, we conducted an in vitro experiment using cultured primary neurons. The neurons were isolated from P0 hyperthermic TRPM2+/+ and TRPM2/ embryos and cultured in differentiation medium for 3 days. By staining with an antibody against TUJ1, we observed no obvious difference between the wild-type and TRPM2 knockout groups in terms of neurite length or number of branches (fig. S8, K to M), suggesting that TRPM2 deficiency induces no phenotype in neurons under heat stress. We also analyzed other stimuli, such as treatment with NaCl (fig. S8, N and Q), change in pH (fig. S8, O and R), and X radiation exposure (fig. S8, P and S), and subsequently found that TRPM2 was not activated by these stimuli. Overall, these findings indicate that well-regulated embryonic cortical development can be disturbed in hyperthermic conditions when TRPM2 is deleted.

To further detail how TRPM2 affects the developing brain in hyperthermia, we sequenced RNA (RNA-seq) to analyze transcriptome-wide changes that arise from the loss of TRPM2. Total RNA was acquired from the cortical tissue of E16 TRPM2 knockout and wild-type mice with mothers that were housed at 38C for 2 hours per day from E14.5 to E16.5. Sequencing was repeated twice for each sample to increase the reliability of the sequencing results. Gene Ontology (GO) analysis revealed that down-regulated genes were associated with cell proliferation and temperature stimuli, including the canonical Wnt signaling pathway, neuronal stem cell division, the detection of temperature stimuli involved in sensory perception, and the negative regulation of cell differentiation. The up-regulated genes were associated with neurogenesis, the regulation of neuronal development, and cell fate commitment (fig. S9A). These data jointly suggest a crucial role for the thermal sensor protein TRPM2 in cortical neurogenesis during hyperthermia. Next, we explored how the deletion of TRPM2 affects neurogenesis at the molecular level during heat stress. Among the differentially expressed genes identified by genome analyses, we selected genes that changed consistently in both sequencing results and finally selected SP5 as a downstream target (fig. S9B and Fig. 4A). To confirm the results of RNA-seq, we performed RT-PCR (fig. S9C) and Western blotting (fig. S9D) and observed that SP5 expression was significantly decreased in samples obtained from the cortex of TRPM2 knockout mice that had experienced heat stress. SP5 is a transcription factor that is downstream of Wnt signaling (17, 19), but the function of SP5 in cortical neurogenesis during hyperthermia has not yet been identified.

(A) The volcano plot indicates differentially expressed genes. The red dots represent up-regulated genes, while the green dots represent down-regulated genes. SP5 is one of the notably down-regulated genes. (B and C) SP5 knockdown results in an abnormal cellular distribution during heat stress. The bar graph shows the population of GFP+ cells in the CP, IZ, and VZ/SVZ (n = 6 embryos from four different mothers). Scale bar, 50 m. (D) Western blot results showing the change in the expression of TRPM2, total -catenin, phosphorylated -catenin, SP5, TUJ1, PH3, and PCNA during heat stress in TRPM2 knockout embryos. Heat stress was applied from E14.5 to E16.5 for 2 hours per day. -Actin was used as the control (n = 3). (E) TRPM2 knockout in vivo during hyperthermia increases GSK3 activity (n = 3). (F) The suppression of TRPM2 in NSCs during heat stress intensifies GSK3 activity (n = 3). (G) Calmodulin (CAM) interacts with GSK3 in hyperthermia (n = 3). (H) Western blot analysis showing changes in the expression levels of TRPM2, total -catenin, phosphorylated -catenin, and SP5 between the brains of room temperature and hyperthermia-exposed embryonic mice. -Actin was used as the loading control (n = 3). (I and J) The intracellular calcium ion concentration increases upon exposure to 38C. After neural stem cells were isolated from the E12.5 cortex cultured at 37C or 38C overnight, they were incubated for 30 min with Fluo-3, and the intracellular calcium fluorescence was quantified with a confocal LSM780 microscope. The graph shows the relative Fluo-3 intensity (n = 30). Scale bar, 15 m. (K) Calcium concentration reduction is caused by TRPM2 knockdown in hyperthermia. NSCs isolated from the E12.5 cortex were infected with a control or TRPM2-shRNA plasmid (red)packaged lentivirus. After 6 hours, the cells were cultured at 38C overnight; then, the calcium concentration was measured (n = 3). Scale bar, 5 m. (L) Western blots showing the expression levels of Flag, total -catenin, and phosphorylated -catenin in primary NSCs with constitutively expressing CAM in hyperthermia conditions. -Actin was used as a control (n = 3). The data are shown as means SEM; two-tailed Students t tests; ***P < 0.001 versus the indicated group.

To investigate the function of SP5 in embryonic brain development, we first stained brain slices with a specific fluorescent antibody against SP5. The in vitro results showed that SP5 was expressed in the nuclei of primary mouse NSCs and was colocalized with progenitor markers, such as NESTIN and SOX2 (fig. S9G). Consistently, SP5 was expressed in vivo in NESTIN-positive NSCs in the VZ/SVZ of the E13.5 cortex (fig. S9H). Furthermore, shRNAs targeting SP5 were constructed, and they effectively silenced the expression of SP5 (fig. S10A). In addition, samples from heat stressexposed mice in which the expression of SP5 was silenced showed an increased number of GFP-positive cells in the CP and a decreased number of GFP-positive cells located in the VZ/SVZ (Fig. 4, B and C). However, the redistribution of GFP-positive cells was not obvious in control mice from mothers that had been housed at room temperature (fig. S10, F and G). Immunostaining for KI67 also showed that fewer GFP+KI67+ cells were observed in the VZ/SVZ in SP5 knockdown mice that had been exposed to heat stress (fig. S10, B and C). In addition, we also found that the percentage of TUJ1-positive cells was obviously increased in neural progenitors that had been infected with an SP5 shRNApackaged lentivirus and had been exposed to hyperthermia (fig. S10, D and E). Overall, these data confirm that SP5 acts downstream of TRPM2 to modulate neurogenesis during heat stress.

To further confirm and elucidate the specific mechanisms by which TRPM2 exerts its effect on NPC proliferation in hyperthermia, we monitored the relative mRNA levels of SP5 and several molecular markers associated with proliferation. Transcription analysis revealed that -catenin mRNA levels were reduced by 40% in TRPM2 knockout NPCs from mice exposed to hyperthermia, while the levels of REST, Hes5, SOX2, CyclinD1, Foxg1, and Olig2 were unchanged (fig. S9C). These findings suggest that -catenin may work together with TRPM2 to regulate embryonic neurogenesis during heat stress. To compare the transcription results to translational outcome, we conducted Western blot analysis. Protein was obtained from E16 cortical tissue from TRPM2 knockout and wild-type mice that were housed at 38C for 2 hours per day from E14.5 to E16.5. Western blot analysis showed an obvious reduction in SP5 and -catenin expression levels. We also found that the phosphorylation levels of -catenin were augmented in TRPM2 knockout mice exposed to hyperthermia. In addition, decreases in expression of the proliferative markers PH3 and PCNA (proliferating cell nuclear antigen) and an increase in the expression of the neuronal marker TUJ1 in TRPM2 knockout mice clarified the role of TRPM2 in embryonic neurogenesis in hyperthermia (Fig. 4D). We obtained similar results in TRPM2 knockdown or TRPM2 overexpression primary NSCs exposed to 38C (fig. S9, E and F). In TRPM2 knockdown NPCs, immunostaining for total -catenin verified that its expression was reduced during heat stress (fig. S10, H and I). We did not observe such an obvious change under room temperature conditions (fig. S6J). Intrigued by the altered phosphorylation levels of -catenin in TRPM2 knockout mice exposed to hyperthermia, we tested the activity of glycogen synthase kinase 3 (GSK3), which is a serine/threonine kinase associated with -catenin phosphorylation. On the basis of the fact that GSK3 activity requires the autophosphorylation of Tyr216 (30), we evaluated protein levels and protein modifications. In TRPM2 knockout mice exposed to hyperthermia, we observed an obvious increase in Tyr216 phosphorylation, suggesting that TRPM2 may negatively regulate GSK3 activity (Fig. 4, E and F). The constitutive overexpression of TRPM2 during hyperthermia intensifies GSK3 activity (fig. S10K). In addition, Western blot analysis showed an increase in the expression of TRPM2, total -catenin, and SP5 and a decrease in the phosphorylation of -catenin (Fig. 4H). Together, these findings suggest that TRPM2 may modulate SP5 transcription by inhibiting the phosphorylation of -catenin and activating -catenin expression.

Intracellular calcium signaling plays key roles in neural development, including neuronal plasticity, neuronal survival, and neurogenesis (31). Studies have shown that intracellular calcium affects the -catenin pathway (32). To further investigate the mechanisms by which TRPM2 plays a role in activating -catenin expression, we measured the calcium ion concentration in NSCs using a confocal microscope and a calcium-sensitive dye. We observed that, when the cells were cultured at 38C overnight, the intracellular calcium levels were significantly increased (Fig. 4, I and J). However, when cells were transfected with the TRPM2-sh1 plasmid with red fluorescent protein (RFP), intracellular calcium decreased (Fig. 4K), suggesting that TRPM2 modulates intracellular calcium. Calmodulin (CAM) is a target of calcium ions within the cell, and once bound to calcium ions, CAM is activated and serves as part of the calcium signal transduction pathway by modulating interactions with various target proteins (33). In our study, we found that CAM interacted with GSK3 (Fig. 4G), and Western blotting showed that phosphorylated -catenin levels were reduced, while total -catenin expression was slightly increased when CAM was overexpressed during heat stress (Fig. 4L). Therefore, these findings suggest that thermal stimuli activate TRPM2, which increases intracellular calcium. Calcium ions can then bind to CAM, thus inhibiting the levels of phosphorylated -catenin and simultaneously activating the expression of -catenin.

On the basis of these results, we suggest that -catenin may enter the nucleus, bind to the SP5 promoter, and modulate the expression level of SP5 during heat stress. To test this hypothesis, we used a luciferase plasmid containing 2 kb of the SP5 promoter and measured luciferase activity (Fig. 5A). We also generated a vector that overexpressed -catenin with a hemagglutinin (HA) tag and characterized its efficiency by Western blotting (fig. S10J). At 39C, we observed more than twofold increase in luciferase activity in cells treated with the -catenin vector compared with cells treated with the empty vector, demonstrating that -catenin binds to the SP5 promoter to exert its function (Fig. 5A). To further determine the specific binding site, we used a chromatin immunoprecipitation (ChIP) assay (Fig. 5B). At 39C, in cells in which -catenin was constitutively expressed, the binding of -catenin 0.5 kb from the SP5 promoter increased, and binding decreased as the distance to the transcription start site increased (Fig. 5B). These differences were not observed at 37C (Fig. 5B). In addition, we analyzed the promoters of other -catenin target genes, such as Axin2 and CyclinD1, in hyperthermia and observed that there was almost no binding of -catenin (fig. S10, L and M), suggesting specificity for SP5.

(A) Flow chart of the luciferase assay in which the SP5 promoter was cloned into the psiCHECK-2 vector. (A) 293FT cells were transfected with an empty vector or a -cateninexpressing vector. Both groups were cotransfected with an SP5 promotercontaining psiCHECK-2 vector and cultured at 39C. After 36 hours of transfection, the relative luciferase activity was quantified and is shown in the bar graph (n = 4). (B) Four pairs of primers were designed for 0.5, 1, and 2 kb from the SP5 transcription start sites and SP5 CDS for ChIP analysis. (B) NPCs cultured in vitro at 39C were infected with a -cateninHAcontaining lentivirus and then pulled down using immunoglobulin G (IgG) or HA-incubated magnetic beads. The relative amount of SP5 promoter was detected via ChIP and real-time PCR and is shown in the bar graph (n = 3). (B) NPCs cultured in vitro at 37C were infected with a -cateninHAcontaining lentivirus and then pulled down with IgG- or HA-incubated magnetic beads. The relative amount of SP5 promoter was determined by ChIP and real-time PCR and is shown in the bar graph (n = 3). (C to F) SP5 overexpression rescues the cortical neurogenesis defects evoked by TRPM2 knockdown (C and D) or knockout (E and F) in hyperthermia. After electroporation (E13.5) and heat stress (E14.5 to E16.5), E16.5 brain slices were stained with anti-TUJ1 antibody. The bar graphs show the percentage of TUJ1+GFP+ cells relative to the total number of GFP+ cells (n = 6 embryos from four different mothers). Scale bars, 50 m. (G) Working model of TRPM2 function in modulating cortical neurogenesis during heat stress. TRPM2 during heat stress increases calcium influx, which inhibits the phosphorylation of -catenin and induces -catenin enrichment on the SP5 promoter, thereby promoting NPC proliferation. The data are shown as means SEM; two-tailed Students t tests; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the indicated group.

To decipher the connection between TRPM2 and SP5 in neurogenesis during heat stress, we performed rescue experiments. We observed that the constitutive expression of SP5 increased the cell populations residing in the VZ/SVZ and ameliorated the irregularity of both the distribution and percentage of GFP+ TUJ1+ cells caused by TRPM2 knockdown (Fig. 5, C and D) and knockout (Fig. 5, E and F) during heat stress in vivo. Therefore, these data demonstrate that SP5 acts downstream of TRPM2 to modulate early cortical development in hyperthermia. Together, our data supported the notion that, during heat stress, TRPM2 increases SP5 levels via the stabilization of -catenin enrichment on the SP5 promoter, thus enhancing NPC proliferation (Fig. 5G).

Cortical neurogenesis is a very sophisticated process that is strictly controlled by a great deal of signaling molecules. If any step of this process goes wrong, abnormal brain functions, and thus neurodevelopmental disorders, result (34). Temperature homeostasis is essential for embryo survival, and heat stress disturbs numerous aspects of fetal development and brain function (35). TRPM2, which has been recently identified as a heat activation protein, plays an important role in the heat response. TRPM2 is also a calcium-permeable channel in the plasma membrane, and a growing body of evidence has shown that calcium signaling heavily affects neural progenitor proliferation during embryonic neurogenesis (10, 36). However, no details as to whether or how TRPM2 affects brain neural development under conditions of heat exist. Here, we used TRPM2 shRNA and knockout mice to investigate the specific functions of TRPM2 in NPC proliferation and differentiation, cortical neuronal morphology, and the mechanisms guiding embryonic neurogenesis under hyperthermic conditions.

In our study, we first confirmed the thermal sensitivity of TRPM2 and then observed that TRPM2 is expressed in NSCs. When expressed during heat stress, TRPM2 augments NPCs in the E15.5 cerebral cortex, providing clues regarding its effect on neurogenesis during hyperthermia. Furthermore, we found that heat stress changes cellular distribution and facilitates NSC proliferation. Previous studies have shown that at room temperature, TRPM2 loss of function leads to increased axonal growth to promote neuronal differentiation (37). Here, we demonstrated that TRPM2 can exert its function earlier, specifically at E13.5, and that during heat stress, the loss of TRPM2 has a more powerful effect on facilitating cortical neurogenesis. However, at room temperature, the phenotype is not obvious. Our data indicate that TRPM2 deficiency in hyperthermia results in a change in cell distribution and proliferation defects with a sharp drop in the NSC pool. We also found that the depletion of TRPM2 during heat stress increases cell cycle exit and premature cell terminal mitosis, ultimately promoting neurons to a more differentiated state. Both proliferation defects and abnormalities in neuronal morphogenesis lead to severe brain illness, such as autism and schizophrenia (38, 39). In addition, we were able to eliminate the influence of cell migration and apoptosis during hyperthermia by knocking out TRPM2. However, why the TRPM2 knockdown phenotype observed during heat stress is more obvious than the phenotype observed under room temperature conditions still needs to be explored.

To investigate the mechanisms underlying the unique phenotype caused by the loss of TRPM2 and hyperthermia, we searched for downstream targets using RNA-seq analysis and found that SP5 expression was decreased upon TRPM2 knockout and hyperthermia. SP5 is a member of the SP1 family of transcription factors, but its function in embryonic brain development is still unclear.

Our research shows that SP5 is abundant in NPCs and that, under conditions of heat, TRPM2 deficiency inhibits SP5 expression from E13.5 to E16.5. This leads to a decrease in the number of GFP-positive cells residing in the VZ/SVZ and results in the promotion of neuronal differentiation. To further decipher how TRPM2 enhances SP5 expression in hyperthermia, we analyzed some signaling molecules and found that total -catenin expression was significantly down-regulated, while the phosphorylation of -catenin was obviously increased upon TRPM2 deficiency and heat stress. -Catenin, which functions in canonical Wnt signaling, is abundant in NSCs and contributes to the modulation of NSC expansion (15). However, specific mechanisms of the protein are not entirely clear. Previous studies have indicated that Wnt/-catenin is associated with intracellular Ca+ (32). Given that TRPM2 is a calcium-permeable channel, we investigated calcium ions during heat stress, and our data showed a decrease in intracellular Ca+ levels upon TRPM2 knockout. Moreover, the overexpression of CAM inhibited the phosphorylation of -catenin and augmented the expression of -catenin. Using a luciferase and ChIP assay, we also confirmed that -catenin binds to the SP5 promoter during heat stress. Unexpectedly, our results indicated that the overexpression of SP5 ameliorates the defects evoked by TRPM2 loss of function in hyperthermia. However, in the future, the current hyperthermia model needs to be further improved because in human, such as fever response, immune system component may take part in this model.

In summary, our findings uncovered a novel mechanism by which TRPM2, a thermo-sensor protein, governs embryonic neural development during heat stress. Furthermore, the neuronal morphology abnormalities in TRPM2 knockout mice exposed to hyperthermia during embryonic development may provide novel insights into neurological disorders associated with heat stress, including maternal fever, and reveal new strategies for treatment. In terms of the mechanism, we found that when TRPM2 is activated by heat and intracellular calcium binds to CAM, the phosphorylation of -catenin is inhibited. Accumulating -catenin then binds to the SP5 promoter to ultimately enhance NPC proliferation.

Pregnant ICR mice were obtained from Vital River Laboratories. All animal-related experiments were conducted in line with the Animal Care and Use Committee of Institute of Zoology, Chinese Academy of Sciences. TRPM2 knockout mice used in our experiments were generated and kept in the Experiment Animal Center of Institute of Zoology, Chinese Academy of Sciences.

To construct shRNA-expressing plasmids, the oligonucleotides were inserted into the pSicoR-GFP (Addgene, 12093) or pSicoR-TOMATO lentiviral vector. The sequences of shRNAs targeting TRPM2 were as follows: TRPM2-sh1, AACCTTAGCTCATGGATTC (13); TRPM2-sh2, GACCTTCTCATTTGGGCCGTT (Sigma). The sequences of SP5 shRNAs were as follows: SP5-sh1, GGATTCAAAGGATTTGCTTTC (17); SP5-sh2, CCCGTCGGACTTTGCACAG (Sigma). The full-length complementary DNAs (cDNAs) of mouse TRPM2, SP5, and CAM were obtained via PCR and cloned into the Flag-tagged pCDH (System Biosciences, CD511B-1) vector for lentivirus packaging.

Human 293FT cells and mouse N2A cells were cultured in Dulbeccos modified Eagles medium (DMEM) that contained 1% penicillin-streptomycin (PS) and 10% fetal bovine serum (FBS). Mouse cortical NPCs from E12.5 mouse cortex were maintained in proliferation medium, which contained 50% DMEM/F12 (Invitrogen), 50% neural basal medium (Invitrogen), epidermal growth factor (EGF) (10 ng/ml), basic fibroblast growth factor (bFGF) (10 ng/ml) (Invitrogen), 1% PS, and 2% B27 (without vitamin A).

The production of lentivirus was obtained by transfecting the core and packaging plasmids into 293FT cells using GenEscort I (Nanjing Wisegen Biotechnology). The virus was gathered at 24, 48, and 72 hours after changing the medium 6 hours after transfection. The primary NSCs for Western blot and immunofluorescence were seeded in 6- or 24-well plates, which were coated with laminin (Invitrogen) and poly-d-lysine (Sigma) (both 10 g/ml) in advance. Twenty-four hours later, half of the medium was changed with proliferation medium without PS. Lentivirus was then added to each well and maintained for 8 hours. Meanwhile, to improve the infection efficiency, polybrene (2 g/ml) was mixed into the medium. Forty-eight hours later, to induce a differentiation state, the medium was displaced with low-glucose DMEM (Gibco) supplemented with 1% FBS (Invitrogen), 1% PS, and 2% B27 (with vitamin A).

IUE was performed as reported previously (40). In brief, pregnant ICR or C57 mice were deeply anesthetized with pentobarbital sodium (70 mg/kg). Subsequently, the recombinant knockdown or overexpression plasmids with a final concentration of 1500 ng/l were mixed with an enhanced GFP plasmid at a ratio of 3:1. In addition, 0.02% Fast Green was included as a tracer. Then, the mixture was microinjected into the lateral ventricle of the embryonic mouse brains using glass capillaries. Five electric pulses of 40 V (950-ms interval; 50-ms duration) were generated using an electroporator (Manual BTX ECM 830) and platinum electrodes. After IUE, the brains of the embryos were collected at E16.5, E17.5, or P1 for further phenotype analysis.

For neural progenitor proliferation analysis, BrdU (50 mg/kg) was injected 2 hours before brain harvesting at E16.5. For neuronal birth dating, BrdU (50 mg/kg) was administrated to pregnant mice at E14.5. For cell cycle exit analysis, BrdU (100 mg/kg) was administrated to pregnant mice 24 hours before brain collection at E15.5.

For heat stress experiments, mice were maintained in their cages, and the cages were put in a large temperature-controlled incubator set at 38 or 39C for 2 hours each day for 2 or 3 days.

Brain slices or cells cultured in vitro were washed with phosphate-buffered saline (PBS) for 5 min, fixed in 4% paraformaldehyde for 20 min, and blocked in 5% bovine serum albumin (Sangon)/PBS containing 1% Triton X-100 (1% PBST) for 1 hour. Subsequently, the primary antibody was diluted with 1% PBST, added, and then incubated at 4C overnight. The following day, the samples to be visualized were rinsed with PBS three times and incubated with secondary antibodies at room temperature for nearly 1.5 hours. The primary antibodies used for immunofluorescence are listed here: rabbit anti-TRPM2 (1:1000; Bethyl Laboratories), rabbit anti-TUJ1 (1:1000; Sigma), mouse anti-BrdU (1:1000; Millipore), rat anti-BrdU (1:1000; Abcam), rabbit anti-CUX1 (1:100; Santa Cruz Biotechnology), rabbit anticleaved caspase-3 (1:1000; Cell Signaling Technology), rabbit anti-PAX6 (1:1000; Millipore), mouse anti-MAP2 (1:1000; Millipore), mouse anti-NESTIN (1:1000; Millipore), rabbit anti-KI67 (1:1000; Abcam), mouse anti-SATB2 (1:300; Abcam), rabbit anti-SP5 (1:200; Bioss), rabbit anti-TBR2 (1:1000; Abcam), rat anti-CTIP2 (1:1000; Abcam), and mouse anti-SOX2 (1:1000; R&D Systems). Secondary antibodies applied were conjugates of Alexa Fluor Cy3, Cy5, or 488 (1:1000; Jackson ImmunoResearch). 4,6-Diamidino-2-phenylindole (DAPI) (2 mg/ml; Sigma) was used for nuclear staining.

Protein was extracted from brain cortical tissue of mouse or cultured cells by lysing with radioimmunoprecipitation assay buffer (Solarbio), with 10 mM phenylmethylsulfonyl fluoride and a protease inhibitor cocktail (Sigma, P8340). Samples were then ultrasonicated and centrifuged at approximately 12,000 rpm for 15 min at 4C. Subsequently, the supernatants were gathered, and protein concentrations were determined using a BCA kit (Thermo Scientific). Next, similar amounts of protein samples were size-separated by 6 to 12% SDSpolyacrylamide gel electrophoresis gels and shifted onto nitrocellulose membranes (Whatman) making use of a semidry transfer system (Bio-Rad). We run multiple gels and normalized to a control. The primary antibodies applied in the Western blots are listed here: rabbit anti-TRPM2 (1:1000; Bethyl Laboratories and Novus Biologicals), rabbit antitotal -catenin (1:1000; Cell Signaling Technology), rabbit antiP-catenin (S33/S37/T41) (1:1000; Cell Signaling Technology), rabbit antinonP-catenin (S33/S37/T41) (1:1000; Cell Signaling Technology), rabbit anti-PCNA (1:500; Santa Cruz Biotechnology), rabbit anti-TUJ1 (1:1000; Bioward), rabbit anti-SP5 (1:500; Bioss), rabbit anti-PH3 (1:1000; Cell Signaling Technology), rabbit anti-TBR2 (1:1000; Abcam), and rabbit anti-Flag (1:1000; Sigma). Secondary antibodies were 800CW Donkey Anti-Mouse IgG (immunoglobulin G), 800CW Donkey Anti-Rabbit, 680LT Donkey Anti-Mouse IgG, and 680LT Donkey Anti-Rabbit IgG (LI-COR Biosciences). Odyssey v3.0 software was used to scan and quantify Western blot bands.

Total RNA was obtained using TRIzol (Invitrogen, 15596) following the manufacturers directions. Reverse transcription of mRNA to first-strand cDNA was achieved using the FastQuant RT Kit (TIANGEN). Quantitative RT-PCR was conducted using the SYBR Green PCR Kit (Takara) with an ABI PRISM 7500 sequence detector system (Applied Biosystems). All reactions were repeated in triplicate for each sample. The primer sequences used for RT-PCR are listed here: TRPM2, AAGGAACACAGACAATGCCTG (forward) and AGGATGGTCTTGTGGTTCGC; TRPM3, TACACCAAAGTCAGCTCCCTG (forward) and GGCCTCTCGTGGAAAGTCAT (reverse); TRPM7, CCCAGCCAAGTTGCAAAAGT (forward) and CTACAGCTTTCTGCTTGCACC (reverse); TRPM8, GTCCTGTGACACCGACTCTG (forward) and CAGTGAGAATCCACGCACCT (reverse); TRPV1, CTCGGATGAATCTGAGCCCC (forward) and GACAACAGAGCTGACGGTGA (reverse); TRPV3, AGTGCTTATAGCAGCGGGTG (forward) and CGTGCAGGATGTTGTTTCCC (reverse); TRPV4, TCCTCTTCTCTTTCCCCGGT (forward) and GTGCCGTAGTCGAACAAGGA (reverse); ANO1, CGAGAAGTACTCGACGCTCC (forward) and TAGTCCACCTTCCGTTTGCC (reverse); TRPA1, TCTGCATATTGCCCTGCACA (forward) and ACTTTCATGCACTCGGGGAG (reverse); BDNF, TACCTGGATGCCGCAAACAT (forward) and GCCTTTGGATACCGGGACTT (reverse); PACAP, ATGACCATGTGTAGCGGAGC (forward) and CGCTGGATAGTAAAGGGCGT (reverse); -catenin, ATCACTGAGCCTGCCATCTG (forward) and GTTGCCACGCCTTCATTC (reverse) (39); SP5, GGCAAGGTGTACGGCAAAAC (forward) and CATAGGTCCCGCGGATTCTC (reverse); REST, GTGCGAACTCACACAGGAGA (forward) and AAGAGGTTTAGGCCCGTTGT (reverse) (41); Hes5, CGCATCAACAGCAGCATAGAG (forward) and TGGAAGTGGTAAAGCAGCTTC (reverse); CyclinD1, GCCTACAGCCCTGTTACCTG (forward) and ATTTCATCCCTACCGCTGTG (reverse) (42); SOX2, GCACATGAACGGCTGGAGCAACG (forward) and TGCTGCGAGTAGGACATGCTGTAGG (reverse); Foxg1, GGCAAGGGCAACTACTGGAT (forward) and CGTGGTCCCGTTGTAACTCA (reverse); Olig2, GGTGTCTAGTCGCCCATCG (forward) and AGATGACTTGAAGCCACCGC (reverse); -actin, GGTGGGAATGGGTCAGAAGG (forward) and AGGAAGAGGATGCGCCAGTG (reverse).

ChIP was performed as follows. To generate the cross-link, in vitro cultured cells were processed with 1% formaldehyde and maintained at room temperature for 10 min. Subsequently, 2.5 M glycine was then added to terminate the cross-link reaction. After washing three times with sterile PBS, the cells were gathered in lysis buffer. Next, the lysates were incubated with 15 l of Dynabeads Protein G (Invitrogen), which was incubated at least 12 hours with 1 g of specific antibody at 4C before incubation. After washing three times with low- and high-salt buffer, the DNA-protein-antibody complex was incubated overnight at 65C to open the covalent bond. Genomic DNA was then obtained using the TIANamp Genomic DNA Kit (TIANGEN Biotech) for subsequent real-time PCR analysis. The primer sequences applied for SP5 promoter are listed here: SP5-CDS, GGCAAGGTGTACGGCAAAAC (forward) and CATAGGTCCCGCGGATTCTC (reverse); SP5-0.5k, AGCTCGGTTGTGGGAGGAA (forward) and TCTTGACAAGCCGCTTGAAG (reverse); SP5-1k, ACCGCTGCCAGGTCGCT (forward) and AGGCAGGGTCAGTCGGC (reverse); SP5-2k, GCTGGGAACCGGTGGCT (forward) and TTGGGAGTATCCTCTTTGGC (reverse); CyclinD1-CDS, TCAAGACGGAGGAGACCTGT (forward) and TTCCGCATGGATGGCACAAT (reverse); CyclinD1-0.5k, CAGCCTCTTCCTCCACTTCC (forward) and AAGCCCTTCTGGAGTCAAGC (reverse); CyclinD1-1k, TCTACTTTAACAATGGTTTGCTGT (forward) and ACAGGGGAAGTCTTGAGAAGG (reverse); CyclinD1-2k, TCAGACATGGCCCTAAACCT (forward) and CATGACCAGTGTGACTCAAAGC (reverse); Axin2-CDS, CAAATGCAAAAGCCACCCGA (forward) and TGCATTCCGTTTTGGCAAGG (reverse); Axin2-0.5k, TACACACTCCCACCACCGA (forward) and ATCTCTGCTCACAGTTTCGGA (reverse); Axin2-1k, TGGAATGCAGTCTATCCCAGC (forward) and AGAAGCTGTGTGACCAGCCA (reverse); Axin2-2k, CCACCACAATCATCCTGGGT (forward) and TCAACTTTAAGGACTGAGGCCA (reverse).

Global transcriptome analysis was conducted by Annoroad Company. Total RNA samples were first tested for quality and quantity using an Agilent 2100 bioanalyzer. After building the library, high-throughput sequencing was used with the Illumina HiSeq 2500 platform. Our RNA-Seq data were deposited in the Gene Expression Omnibus database with the accession number of GSE113954.

The CRISPR-Cas9 system was used to construct TRPM2 knockout mice. During the process, two guide RNAs (gRNAs) (gRNA5, GCCAGTTCTTCTCCGGTCCAAGG; gRNA3, TATTGCTTCGTCGGAGATTGGGG) were used to cleave the whole genome sequence of TRPM2 to approximately 800 base pairs (bp). The genotyping primers designed for the TRPM2 knockout mice were TRPM2-2717F GAAGGGAAACGGGTGGATGT and TRPM2-4007R GCAGGTCTCCTCAACCAGTC. The length of PCR product was 511 or 1291 bp for TRPM2 knockout mice or wild-type mice, respectively.

Apoptotic cells were identified with immunostaining using an antibody targeting cleaved caspase-3.

293FT cells (4 104) were seeded into a 24-well plate and transfected with 0.5 g of luciferase plasmid containing an SP5 promoter and empty vector or with 0.5 g of luciferase plasmid containing an SP5 promoter and -catenin overexpression vector, using GenEscort I (Nanjing Wisegen Biotechnology). Thirty-six hours after transfection, luciferase activity was measured using the Dual-Luciferase Assay System (Promega) and GloMax 96 Microplate Luminometer (Promega).

All images were taken with a Zeiss LSM780 confocal microscope and analyzed with Photoshop CS6 (Adobe). ZEN 2010 was applied for image acquisition and processing. Brightness or expression quantity was measured using ImageJ when needed.

All statistical analyses in this study were performed and plots were generated using GraphPad Prism7.0 software. Results are represented as means SEM. Two-tailed Students t tests and one-way analysis of variance (ANOVA) were used for statistical comparisons. The differences were regarded as statistically significant with *P < 0.05, **P < 0.01, and ***P < 0.001. n.s. means not significant.

Acknowledgments: Funding: This work was supported by grants obtained from the National Science Fund for Distinguished Young Scholars (81825006), CAS Strategic Priority Research Program (XDA16010301), National Key R&D Program of China (2019YFA0110300 and 2018YFA0108402), National Science Foundation of China (31730033 and 31621004), and K. C. Wong Education Foundation. Author contributions: Y.L. performed the experiments, analyzed data, and wrote the manuscript. J.J. conceived and supervised this project. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

View post:
Deficiency of TRPM2 leads to embryonic neurogenesis defects in hyperthermia - Science Advances

Read More...

Hydrogel controls inflammation to speed healing – Futurity: Research News

January 1st, 2020 7:45 pm

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have established a baseline set of injectable hydrogels that show promise to help heal wounds, deliver drugs, and treat cancer.

Critically, theyve analyzed how the chemically distinct hydrogels provoke the bodys inflammatory responseor not.

The researchers designed the hydrogels to be injectable and create a mimic of cellular scaffolds in a desired location. They serve as placeholders while the body naturally feeds new blood vessels and cells into the scaffold, which degrades over time to leave natural tissue in its place. Hydrogels can also carry chemical or biological prompts that determine the scaffolds structure or affinity to the surrounding tissue.

We dont want zero inflammation; we want appropriate inflammation.

The study demonstrates it should be possible to tune multidomain peptide hydrogels to produce appropriate inflammatory response for what theyre treating.

Weve been working on peptide-based hydrogels for a number of years and have produced about 100 different types, says Jeffrey Hartgerink, a chemist and bioengineer at Rice University. In this paper, we wanted to back up a bit and understand some of the fundamental ways in which they modify biological environments.

The researchers wanted to know specifically how synthetic hydrogels influence the environments inflammatory response. The two-year study offered the first opportunity to test a variety of biocompatible hydrogels for the levels of inflammatory response they trigger.

Usually, we think of inflammation as bad, Hartgerink says. Thats because inflammation is sometimes associated with pain, and nobody likes pain. But the inflammatory response is also extremely important for wound healing and in clearing infection.

We dont want zero inflammation; we want appropriate inflammation, he says. If we want to heal wounds, inflammation is good because it starts the process of rebuilding vasculature. It recruits all kinds of cells that are regenerative to that site.

The labs tested four basic hydrogel typestwo with positive charge and two negativeto see what kind of inflammation they would trigger. They discovered that positively charged hydrogels triggered a much stronger inflammatory response than negatively charged ones.

Among the positive materials, depending on the chemistry generating that charge, we can either generate a strong or a moderate inflammatory response, Hartgerink says. If youre going for wound-healing, you really want a moderate response, and we saw that in one of the four materials.

But if you want to go for a cancer treatment, the higher inflammatory response might be more effective, he says. For something like drug delivery, where inflammation is not helpful, one of the negatively charged materials might be better.

Basically, were laying the groundwork to understand how to develop materials around the inflammatory responses these materials provoke. That will give us our best chance of success.

Researchers at Texas Heart Institute (THI) helped analyze the cellular response to the hydrogels through multidimensional flow cytometry.

The results of this work lay the groundwork for specifically tailoring delivery of a therapeutic by a delivery vehicle that is functionally relevant and predictable, says Darren Woodside, vice president for research and director of the flow cytometry and imaging core at THI. Aside from delivering drugs, these hydrogels are also compatible with a variety of cell types.

One of the problems with stem cell therapies at present is that adoptively transferred cells dont necessarily stay in high numbers at the site of injection, he says. Mixing these relatively inert, negatively charged hydrogels with stem cells before injection may overcome this limitation.

Hartgerink says the work is foundational, rather than geared toward a specific application, but is important to the long-term goal of bringing synthetic hydrogels to the clinic.

We have been speculating about a lot of the things we think are good and true about this material, and we now have more of a sound mechanistic understanding of why they are, in fact, true, Hartgerink says.

The research appears in Biomaterials.

Additional coauthors are from Rice and the Texas Heart Institute. The National Institutes of Health, the Welch Foundation, the Mexican National Council for Science and Technology, the National Science Foundation, and a Stauffer-Rothrock Fellowship supported the research.

Source: Rice University

Originally posted here:
Hydrogel controls inflammation to speed healing - Futurity: Research News

Read More...

OncoImmune Announces Approval of IND Application for ONC-392 The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy…

January 1st, 2020 7:45 pm

DetailsCategory: AntibodiesPublished on Wednesday, 01 January 2020 12:23Hits: 302

ROCKVILLE, MD, USA I December 30, 2019 I OncoImmune, Inc. announced today that its Investigational New Drug (IND) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by the U.S. Food and Drug Administration (FDA). The IND approval enables OncoImmune to begin a Phase 1A/1B clinical trial of ONC-392 that is designed to assess the safety, pharmacokinetics, and efficacy of ONC-392 as a single agent in advanced solid tumors and in combination with anti-PD(L)1 standard of care in Non-

ONC-392 was developed based on the research of OncoImmunes Founders, Drs. Yang Liu and Pan Zheng, who proposed a new theory to improve both the efficacy and safety of immunotherapy drugs. The theory calls for preservation of the CTLA-4 immune checkpoint for safer and more effective immunotherapy. (https://www.sciencedirect.com/science/article/pii/S0165614719302639). This groundbreaking research was published in three papers in Cell Research in 2018 and 2019. The two 2018 papers were recognized with the Sanofi-Cell Research Outstanding Paper Award of 2018 (https://www.nature.com/articles/s41422-019-0248-2).

ONC-392 is OncoImmunes second drug product candidate and the approval of this IND is an important milestone for OncoImmune, said Yang Liu, President and CEO of OncoImmune. Unlike other anti-CTLA-4 antibodies that cause lysosomal degradation of CTLA-4, ONC-392 preserves CTLA-4 recycling and thus maintains CTLA-4 function outside of the tumor microenvironment while allowing more effective CTLA-4-targeted depletion of regulatory T cells within the tumor. The truly novel and differentiated mechanism of action of this drug has the potential to improve therapeutic outcomes while significantly reducing toxicity.

We are very excited to test the potential of this novel antibody in cancer patients, said Pan Zheng, Chief Medical Officer of OncoImmune, Inc.

The CMC development and GMP manufacturing of the drug substance and drug product were performed by WuXi Biologics, a leading global open-access biologics technology platform for the ONC-392 program. Throughout the development program from DNA to IND, we were very impressed by WuXi Biologics expertise and professionalism, and we could not have picked a better partner for this project, said Martin Devenport, OncoImmunes Chief Operating Officer.

About OncoImmune, Inc.

OncoImmune (www.oncoimmune.com) is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases. OncoImmune is based in Rockville, Maryland.

OncoImmunes lead product, CD24Fc, is a novel therapeutic that regulates host inflammatory response to tissue injuries and which has broad implications in the pathogenesis of cancer, autoimmune disease, metabolic syndrome and graft-versus-host disease (GvHD). CD24Fc has completed a Phase IIa trial for the prophylactic treatment of acute Graft versus Host Disease (GvHD) in leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) and resulted in a significant improvement in 180 Day Grade III-IV GVHD Free Survival, the Phase III primary endpoint. CD24Fc prophylaxis also resulted in a reduced relapse and, compared to match controls, CD24Fc demonstrated improvement in Overall Survival, Non-Relapse Mortality and Relapse-Free Survival. A dose-dependent reduction in severe (Grade > 3) mucositis was also observed. A 20 patient open label dose expansion cohort at the recommended clinical dose is fully enrolled and the drug continues to perform very well. A Phase III study is anticipated to start in early 2020.

SOURCE: OncImmune

Read this article:
OncoImmune Announces Approval of IND Application for ONC-392 The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy...

Read More...

Conway supports man fighting rare double diagnosis of MS, ALS – THV11.com KTHV

January 1st, 2020 7:43 pm

CONWAY, Ark. A Conway man has spent many years living with Multiple Sclerosis, but this year he was also diagnosed with ALS, or Lou Gherigs Disease.

For the Nobles family, every day with their father, Greg, is a treasured moment.

"I was first diagnosed 16 years ago with MS," said Greg Nobles.

Life has been a challenge since, but it was this January when his health began to decline severely.

Greg lost all mobility. After getting treated for his symptoms and not seeing a difference is when neurologists confirmed Greg also suffers from ALS, a nervous system disease weakening muscles with no cure.

"Doctors have never seen a patient with both before, said Bailey Smith, Gregs daughter. Being diagnosed MS first, we got 15 good years with him versus the ALS now.

RELATED: A final fundraiser for the man who boosted the ice bucket challenge

Once active and known as one of the best hairstylist in town, Gregs now homebound hoping for relief from the pain he endures.

"My husband passed away from ALS in 2004, so I know the journey they are going on, said Diana Kirkland, a hair client of Gregs.

Kirkland knew she needed to do something for the Nobles.

She owns Legacy Acres in Conway.

This week shes preparing her space for a fundraising event Friday night to raise money so Greg can receive stem cell therapy, an expensive procedure done in Mexico, but one that will reduce his discomfort.

"If I could just get some mobility back, it's worth it, said Greg.

Greg has already received two rounds of stem cell therapy.

RELATED: Arkansas man raises money for charity by streaming 24-hour gaming session

Fortunately, hes starting to notice relief in his left leg.

But with ALS, hes given 3 to 5 years to live, but with a community coming together to help, his family hopes that love and support will give them more time with him.

"It means everything to us, said Smith. To continue to get stem cells for us, my babies to see my dad keep fighting.

Greg Nobles Fundraising Dinner is at Legacy Acres, 100 Legacy Acres Drive, in Conway on Friday night beginning at 6 p.m.

Everyone is invited. The event will have live music, a silent auction, catered food provided by Catering By S and I.

There will also be a donation table set up for a stem cell therapy fund.

Here is the original post:
Conway supports man fighting rare double diagnosis of MS, ALS - THV11.com KTHV

Read More...

Stem Cell Therapy Market 2020 Analysis by Treatment, Application, Technology, Therapy With Regional Outlook & Forecast To 2025 – The Picayune…

January 1st, 2020 7:42 pm

Growth of Global Stem Cell Therapy Market Size is favored by cumulative factors like development of advanced genome-based cell analysis techniques, soaring awareness of the therapeutic potency of stem cells, detection of novel stem cell lines, and developments in infrastructure related to stem cell banking and processing, and increasing public-private investments for development of stem cell therapies.

In the upcoming years, North America is likely to dominate the global stem cell therapy market share. The U.S. dominates the market which is followed by Canada. Stem cell therapy is powered to cure diseases like diabetes and cancer. There is an increase in occurence of such diseases and higher awareness for the treatment of such diseases is propelling stem cell therapy market. New product innovation & launching, increase in a number of clinical trials for evaluation of the therapeutic potential and higher adoption of these therapies & procedures is fueling market growth. Presence of numerous centers and organization that are engaged in R&D related to new stem cell therapy is likely to led lucrative market growth.

Get more insights at:Global Stem Cell Therapy Market 2020-2025

Europe holds second position in the lucrative market of stem cell therapy. This is attributed to development of efficient & advanced technologies and growing investment in healthcare industry.

The Asia Pacific is projected to exhibit the highest growth in the market. The key countries that are expected to experience fastest development are India and China. The higher adoption of grants by several funding agencies and government for scientific researches is anticipated to stimulate the regional market growth. Investment of leading players for launch and development of newer technologies and increase in healthcare expenditure are also anticipated to up surge the Asia-Pacific market growth of stem cell therapy.

The Middle East & Africa and Latin America regions are expected to show slow growth in the forecast period. Rising awareness about the SC therapies, growing expenditure in the healthcare sector, rapid development in the infrastructure of healthcare and adoption of western technologies and lifestyle is expected to fuel the growth of the stem cell therapy market.

In terms of types of global stem cell therapy market is bifurcated into autologous stem cell therapy and allogeneic stem cell therapy. The segment of allogeneic stem cell therapy is likely to command largest global stem cell therapy market share. This is attributed to easy production scale-up process, escalating commercialization of allogeneic stem cell therapy products, the extensive therapeutic applications of allogeneic stem cells and mounting number of clinical trials related to allogeneic stem cell therapies.

Based on therapeutic application, the global stem cell therapy industry has wide range of categories which includes musculoskeletal disorders, cardiovascular diseases, gastrointestinal diseases, wounds and injuries, surgeries, and other applications. The musculoskeletal disorders sector is anticipated to dominate the global stem cell therapy market by holding largest share. This is attributed to the high prevalence of bone & joint diseases, musculoskeletal disorders, escalating availability of stem cell-based products for the treatment of musculoskeletal disorders and higher patient preference for effective & early treatment strategies.

Get more details about Global Stem Cell Therapy Market:

https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

The global stem cell therapy market is niche industry with soaring global and local companies involved in the commercialization and development of stem cell therapy products. Anterogen Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea), Osiris Therapeutics, Inc. (U.S.) and Pharmicell Co., Ltd. (South Korea) are the prominent market players of the global stem cell therapy market. The major strategies adopted by leading market players include expansions, partnerships, new product launches and approvals, and agreements to achieve growth in the global stem cell therapy market.

Key segments of Global Stem Cell Therapy Market

Based on cell source, the market has been segmented into,

Based on therapeutic application, the market has been segmented into,

Based on region, the market has been segmented into,

What to expect from the upcoming report on Global Stem Cell Therapy Market:

Future prospects and current trends of the global stem cell therapy market by the end of forecast period (2018-2025)

Information regarding technological progressions as well as innovations taking place in developing economies

Supportive initiatives by government likely to influence the market dynamics

Trends, drivers, opportunities, restraints, challenges and key developments in the market

In-depth analysis of different market segmentations including regional segmentations, and product types

Deep analysis about the competitive landscape of the market and the initiatives by them to improve this market

For Any Query on the Stem Cell Therapy Market:

https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About US:

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX 75204, U.S.A

Phone No.: USA: +1 972-362 -8199 / +91 9665341414

This post was originally published on The Picayune Current

Originally posted here:
Stem Cell Therapy Market 2020 Analysis by Treatment, Application, Technology, Therapy With Regional Outlook & Forecast To 2025 - The Picayune...

Read More...

Stroke Therapeutics Market by Type and Geography – Global Forecast and Analysis 2019-2023 – GlobeNewswire

January 1st, 2020 7:42 pm

Dublin, Dec. 31, 2019 (GLOBE NEWSWIRE) -- The "Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The stroke therapeutics market analysis considers sales from both ischemic stroke and hemorrhagic stroke types. The analysis also considers the sales of stroke therapeutics in Asia, Europe, North America, and ROW. In 2018, the ischemic stroke therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as availability of patient assistance programs will play a significant role in the ischemic stroke therapeutics segment to maintain its market position. Also, the global stroke therapeutics market report looks at factors such as high-risk factors for stroke, strong pipeline, and growth of the geriatric population. However, high level of genericization in the market, availability of substitutes, and clinical trial failures may hamper the growth of the stroke therapeutics industry over the forecast period.

Globally, stroke is the second-leading cause of death among adults. The high prevalence of stroke is attributed to the increase in the incidence of ischemic strokes and hemorrhagic strokes, mainly because of the increasing presence of high-risk factors over the years. The major risk factors such as high blood pressure, high cholesterol levels and obesity, heart diseases, and diabetes are increasing the number of strokes that results in several deaths across the world. The risk of stroke also increases due to excessive smoking and alcohol consumption. Such risk factors will lead to the expansion of the global stroke therapeutics market at a CAGR of almost 5% during the forecast period.

The global stroke therapeutics market is expected to benefit from the development of novel therapies, such as stem cell therapies. Owing to the high prevalence of stroke, there is a huge need for safe and innovative novel therapies to treat stroke. Therefore, several companies are developing novel drugs for the treatment of stroke. The development of stem cell therapy will have a major impact on upcoming stroke therapeutics, as it has fewer side effects and regenerative properties. Some of the other novel drugs currently under various stages of development in the stroke therapeutics market are PSD-95 antagonist NA-1 developed by NoNO and 3K3A-APC developed by ZZ Biotech LLC. Such development of novel therapies with fewer side effects is expected to have a positive impact on the overall market growth.

With the presence of several major players, the global stroke therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading stroke therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.

Also, the stroke therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPEPART 04: MARKET SIZINGPART 05: FIVE FORCES ANALYSISPART 06: MARKET SEGMENTATION BY TYPE

PART 07: CUSTOMER LANDSCAPEPART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORKPART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDSPART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/af16zt

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023 - GlobeNewswire

Read More...

Next Generation Sequencing Market to Exhibit Impressive Growth by 2025 | Agilent Technologies, New England Biolabs, Oxford Nanopore Technolgies…

January 1st, 2020 7:41 pm

Global Next Generation Sequencing (NGS) Market, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing, and Others), by Application (Drug Discovery, Personalized Medicine and Genetic Screening, Disease Diagnosis, Agriculture and Animal Research, and Others), by End User (Hospital, Research Centers, Pharma and Biotech Firms, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is projected to exhibit a healthy CAGR over the forecast period (2019 2025)

Get Research Insights @Next Generation Sequencing Market Size 2019-2025

Reducing NGS capital cost associated with declining sequencing cost, developments in NGS platforms and developing scenario of reimbursement and regulatory for diagnostic tests based on NGS are projected to fuel the next-generation sequencing market growth. Industry of next-generation sequencing is a market that contains infinite companies present in the production of consumables & kits, instruments and advancement of software to foster the NGS market growth in the coming years.

In addition, the usage of the cloud computing in NGS for the management of data in evolving economies are projected to offer opportunities to the manufacturers of next generation sequencing in the coming future. Developments of technology in cloud computing and data integration, demand for clinical diagnostic and increase in demand for scientific research are the factors that are responsible for the growth of global next generation sequencing market.

In addition, growing acceptance of next generation sequencing technology in several end-users and increasing funds in the activities of research & development is boosting the growth of next-generation sequencing market. Moreover, developing applications of NGS in personalized medicine and food testing is anticipated to drive the next generation sequencing market growth in the coming years. Although, scarcity of the skilled professionals are hindering the next generation sequencing market growth.

Browse Complete Next Generation Sequencing (NGS) Market Report @https://www.adroitmarketresearch.com/industry-reports/next-generation-sequencing-market

Legal and ethical discussions are the part of medical research. Journals and funding agencies are submitting the genomic data from the research contributors to the databases are allowing the investigators for controlling the data. The samples and data are sent from databases without the approval of participant by pushing them at risk. Unidirectional flow of data are creating the sense of distrust and exploitation. As a result, ethical and legal issues are hampering the next generation sequencing market growth.

Development of next generation sequencing market is accredited to the significant reduction in the costs of sequencing. For instance, price of sequencing in 2006 was approximately $15 Billion, which ultimately reduced to $6000 Billion in 2014. Several key players like Illumina and Roche have announced the techniques of sequencing which have decreased the cost related to sequencing.

Growing attention of NGS is projected to fuel the usage of precision medicine in oncology on the basis of research setting to the clinical cancer is increasing the growth of global next generation sequencing industry. Market players are involved in studying the novel and existing tests to create the criteria for medical necessity for medical and clinical policies. Global next generation sequencing market trends are developed understanding of the genetic markers of resistance and virulence offered by next generation sequencing is estimated to boost the demand for the technology of diagnosing the infectious disease.

Make an Enquire to Buy This Report @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/720

Global next generation sequencing market are end-user, application, technology, product & service and region. On considering the end-user, market is divided into biotechnology & pharmaceutical companies, clinics & hospitals, academic institutes and research centers and more. On the basis of application, market is divided into animal & agricultural research, drug discovery, other diagnostic applications, reproductive health diagnostics, infectious disease diagnostics, cancer diagnostics, diagnostics and much more. Based on technology, market is divided into nanopore sequencing, single-molecule real time sequencing, ion semiconductor sequencing, sequencing by synthesis and more. By product & service, market is divided into bioinformatics, sequencing services, services for NGS platforms, NGS platforms, NGS consumables and pre-sequencing products and services. Bioinformatics further subdivided into NGS storage management & cloud computing solutions, NGS data analysis services and NGS data analysis workbenches & software whereas sequencing services are divided into De Novo and Whole genome sequencing, RNA sequencing, Custom Panels and Exome and Targeted Sequencing. NGS platforms are further sub-divided into Oxford Nanopore Technologies, Pacific Biosciences, ThermoFishcer Scientific, Illumina and others. Pre-sequencing products & services market is divided into quality control, target enrichment & library preparation, size selection, A-tailing, End Repair and DNA fragmentation.

Geographically, regions involved in the global next-generation sequencing (NGS) market analysis are Europe, North America, Asia Pacific and Rest of the World. North America holds the largest global next generation sequencing market share followed by Europe. Asia Pacific is expected to rapidly grow in the coming years.

Key players involved in the next generation sequencing market are Agilent Technologies, New England Biolabs, Oxford Nanopore Technolgies Limited, Thermo Fischer Scientific and more.

Key Segments in the Global Next Generation Sequencing Market are-

By End-User, market is segmented into:

By Application, market is segmented into:

By Technology, market is segmented into:

By Product & Service, market is segmented into:

By Regions market is segmented into:

Early Buyers will Get 10% Discount on This Premium Research now @https://www.adroitmarketresearch.com/contacts/discount/720

What to expect from the Global Next Generation Sequencing Market report?

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

About Adroit Market Research:

Adroit Market Research provide quantified B2B research on numerous opportunistic markets, and offer customized research reports, consulting services, and syndicate research reports. We assist our clients to strategize business decisions and attain sustainable growth in their respective domain. Additionally, we support them with their revenue planning, marketing strategies, and assist them to make decisions before the competition so that they remain ahead of the curve.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 (214) 884-6068 / +91 9665341414

Original post:
Next Generation Sequencing Market to Exhibit Impressive Growth by 2025 | Agilent Technologies, New England Biolabs, Oxford Nanopore Technolgies...

Read More...

Six times SA was at the cutting edge of science in 2019 – TimesLIVE

December 31st, 2019 3:46 pm

From genetics and engineering to astronomy and geoscience, SA has been the setting for a string of major scientific advances this year.

Geneticists found themselves looking backwards as well as forwards in attempts to put right a century-old wrong.

The remains of 11 individuals in the University of Cape Towns skeletal collection were found to have been unethically obtained in the 1920s. It turned out that nine of the individuals were Khoisan farmworkers whose remains were dug up on a farm near Sutherland in the Northern Cape. A major restitution process will lead to their reburial next year.

At the request of the individuals descendants, a multidisciplinary scientific study determined the estimated age, gender and medical condition of each individual and assessed isotopes from bones and teeth to shed light on the their habitat, living conditions and diets.

DNA experts were able to establish ancestral genetic relationships while archaeologists conducted a survey of the cemetery and the disturbed graves. Finally, the individuals faces were recreated.

View original post here:
Six times SA was at the cutting edge of science in 2019 - TimesLIVE

Read More...

Molecular Microbiology Market Insightful Analysis Of Current Scenario And Future Growth Prospect Including Key Players ( BioMerieux, Danaher…

December 31st, 2019 3:46 pm

HTF MI released a new market study on Global Molecular Microbiology Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand in depth analysis. Global Molecular Microbiology Market by Type (, Quantitative PCR Detection Diagnostic Kits & Pathogenic Microorganisms Diagnostic Kits), by End-Users/Application (Human & Veterinary), Industry Size, Organizations, and Region Forecast and outlook to 2025. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, focused opinions, details, and industry certified market data. The research study provides estimates for Global Molecular Microbiology Forecast till 2025*. Some of the key players profiled are Roche, Qiagen, Illumina, Abbott, Hologic, BioMerieux, Danaher (Cepheid), Myriad Genetics, DAAN Gene, Agilent, Genomic Health, BD & Foundation Medicine etc.

Get Access to sample pages @https://www.htfmarketreport.com/sample-report/1618256-global-molecular-microbiology-market-9

The Global Molecular Microbiology market report more focuses on top industry leaders and explores all essentials facets competitive landscape. It explains potent business strategies and approaches, consumption propensity, regulatory policies, recent moves taken by competitors, as well as potential investment opportunities and market threats also. The report emphasis crucial financial details of major manufacturers including year-wise sale, revenue growth, CAGR, production cost analysis, and value chain structure.

In 2018, the Global Molecular Microbiology market size was USD XX and is forecast to reach Million YY USD in 2025, growing at a CAGR of xx%. The objectives of this study is to define, market segment having opportunity, and to project the size of the Molecular Microbiology market based on company, product type, application and key regions.

Besides, the report also covers segment data, including: type segment, industry segment etc. cover different segment market size. Also cover different industries clients information, which is very important for the Major Players. If you need more information, please contact HTF MI at [emailprotected]

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2018 currency rates.

Competition Analysis

Global Molecular Microbiology Market Vendor Landscape: The analysts authoring the publication explain the nature and future changes in the competitive scenario of the worldwide companies that are profiled in the publication guide, some of key players that includes in the study are Roche, Qiagen, Illumina, Abbott, Hologic, BioMerieux, Danaher (Cepheid), Myriad Genetics, DAAN Gene, Agilent, Genomic Health, BD & Foundation Medicine

The Study is segmented by following Product Type , Quantitative PCR Detection Diagnostic Kits & Pathogenic Microorganisms Diagnostic Kits

Major applications/end-users industry are as follows Human & Veterinary

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/1618256-global-molecular-microbiology-market-9

Region Segmentation: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Spain, Russia, Central & South America, Brazil, Rest of Central & South America, Middle East & Africa, GCC Countries, Turkey, Egypt & South Africa

** Customized Report with detailed 2-level country level break-up can also be provided.North America (United States, Canada)South America (Brazil, Argentina, Rest of South America)Asia (China, Japan, India, Korea, RoA)Europe (Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe)Others (Middle East, Africa)

In this study, the years considered to estimate the market size of Global Molecular Microbiology are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

Highly Competitive Market [Perfect Competitive Market C4 Index Beyond 50% of Total Market Share] Focus of the study is to analyse characteristics that affect the nature of competition and pricing. Identifying Influencing factors keeping Global Molecular Microbiology Market Intense, factored with periodic analysis of CR4 & CR8 concentration ratio. In-depth Competitive analysis at product and Strategic business level. Predictive analysis on upcoming trends and changes in consumer behaviour. To analyse the competitive developments, such as new product launch and merger & acquisition, in the Global Molecular Microbiologymarket

Buy full research report @https://www.htfmarketreport.com/buy-now?format=1&report=1618256

Key Stakeholders/Global Reports: Molecular Microbiology Manufacturers Molecular Microbiology Distributors/Traders/Wholesalers Molecular Microbiology Sub-component Manufacturers Industry Association Downstream Vendors

Following would be the Chapters to display the Global Molecular Microbiology market.

Chapter 1, to describe Definition, Specifications and Classification of Molecular Microbiology, Applications of Molecular Microbiology, Market Segment by Regions;Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Molecular Microbiology, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, to show the Regional Market Analysis that includes North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey & Rest of Middle East & Africa, Molecular Microbiology Segment Market Analysis (by Type);Chapter 7 and 8, to analyze the Molecular Microbiology Segment Market Analysis (by Application) Major Manufacturers Analysis of Molecular Microbiology;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type [, Quantitative PCR Detection Diagnostic Kits & Pathogenic Microorganisms Diagnostic Kits], Market Trend by Application [Human & Veterinary];Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, to analyze the Consumers Analysis of Global Molecular Microbiology;Chapter 12,13, 14 and 15, to describe Molecular Microbiology sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/1618256-global-molecular-microbiology-market-9

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Here is the original post:
Molecular Microbiology Market Insightful Analysis Of Current Scenario And Future Growth Prospect Including Key Players ( BioMerieux, Danaher...

Read More...

Bioinformatics Market Analysis and Forecast up to 2020 – News Cast Report

December 31st, 2019 3:46 pm

Prominent participants in the global market for bioinformatics includeID Business Solutions, Ltd., Illumina, Inc., GenoLogics Life Sciences Software, Inc., Affymetrix, Inc., Life Technologies Corporation, Agilent Technologies, Inc., CLC bio A/S, and Accelrys, Inc. In order to march ahead, they are seen investing heavily in research and development of more cutting-edge products.

A report by Transparency Market Research projects theglobal bioinformatics marketsworth to be around US$9.1 bn by 2018-end.

The global market for bioinformatics has been segmented broadly into platforms, content management, and services by the report. They are all commercially available for sorting the data accumulating form research and development projects by leveraging bioinformatics. Among them, the bioinformatics platform comprising of sequence alignment platforms, sequence manipulation platforms, structural analysis platforms, and sequence analysis platforms is leading vis--vis consumption. This is because of their growing application in the process of research and development for drug discovery. Geographically, North America leads the market on account of the huge allocations towards cutting-edge research and development, swift uptake of latest technologies, and a well etched out regulatory framework in place.

Request Sample of Bioinformatics Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=656

Pressing Need to Cure a Range of Ailments Boosts Adoption of Bioinformatics

Bioinformatics finds application in managing the data emanating from research and development in the domain of life science, biopharmaceutical, and biotechnology. Its market has been seeing a steady upswing owing to the increasing usage of IT applications in the domain of healthcare sector to store, process, access, and retrieve data. Besides, the pressing need to treat several diseases effectively alongside the demand for preventive solutions are also having a positive impact on the market. Growing thrust on research and development has been a major catalyst too.

Study of Molecular Medicine and Genetics Augurs Well for Market

Bioinformatics finds usage in preventive medicine, molecular medicine, drug development, and gene therapy. Currently, the molecular medicine is stoking their demand majorly. They also find usage in genetic research for antibiotic resistance, veterinary science, and microbes. All these are decidedly impacting their market positively.

Elaborates the lead analyst of our report, The growth in the worldwide market for bioinformatics market is being propped up by the solid progress in the study of genetics. As per estimates, the volume of genetic data entries would rise twofold every 15 years. And with the total amount of generated data being too large to be supported by the present data entry programs, savvy companies are seen resorting to more advanced models of bioinformatics.

Request for a Discount on Bioinformatics Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=656

Key Players Train Sights on Asia Pacific

At present, developed geographies of Europe and North America are where most of the development in the bioinformatics has occurred. This is because of the huge amounts allocated for research and development and swifter deployment of newest technologies. However, key players have also set their gaze upon Asia Pacific with its fast developing infrastructure in scientific fields, the improvements in government and private funding, and the rising literacy and awareness rates.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:sales@transparencymarketresearch.comWebsite:http://www.transparencymarketresearch.com

See the original post:
Bioinformatics Market Analysis and Forecast up to 2020 - News Cast Report

Read More...

Relieve Joint Pains Caused By Arthritis This Christmas By Having This Treat – International Business Times

December 31st, 2019 3:45 pm

KEY POINTS

Arthritis is a catch-all term for a series of painful conditions that cause tenderness and swelling of one or more joints.Rheumatoid arthritis and osteoarthritis are two of the most common types of arthritis.

The Joints Affected

Osteoarthritis usually affects the knees, spine, hips, and hands. Rheumatoid arthritis, on the other hand, oftentimes affects the wrists, hands, and feet.

While there is no cure for this painful condition, there are some lifestyle interventions that have been proven to alleviate the symptoms. Among these is consuming a well-known Christmas treat. gingerbread treatment for arthritis Photo: NickyPe - Pixabay

A Delicious Treatment

A key ingredient of the gingerbread man can help alleviate arthritis symptoms. Several studies have shown ginger extract helps a lot in alleviating joint pains caused by arthritis.

One prominent research revealed that ginger extract has the same efficacy as ibuprofen in the first treatment period. Another study also found that Echinacea and ginger supplements can reduce pain and inflammation after knee surgery. Echinacea is a well-known herb that is often taken to treat colds and flu.Researchers also discovered that highly concentrated doses of ginger extracts are very effective for the treatment of osteoarthritis of the knee.

The Study

The research involved volunteers who are experiencing moderate-to-severe knee pain. After taking ginger extracts, the volunteers said they felt lesser pain in their knees upon standing and after walking.

An animal study also revealed ginger could help relieve joint pains caused by rheumatoid arthritis. The findings of the researchers were further strengthened by another research which found ginger to be very effective in relieving human muscle pain due to an exercise-induced injury.

Volunteers who ingested at least two grams of raw or heated ginger reported the pain they felt somewhat lessened. The inflammation was also reduced. The volunteers applied ginger extract three times a day for twelve weeks, and during this time, they report having reduced levels of pain.

Researchers say that, while raw and heated gingers are equally helpful in alleviating joint pains, heat-treated ginger is believed to have a stronger effect. The studys findings also suggest applying a ginger-laced gel or cream directly to the affected area can also alleviate the painful symptoms.In many studies, researchers say ginger extracts can greatly improve osteoarthritis in the knees when it is applied topically.

View post:
Relieve Joint Pains Caused By Arthritis This Christmas By Having This Treat - International Business Times

Read More...

To Your Health: Study paves way to better understanding, treatment of arthritis – The Chief News

December 31st, 2019 3:45 pm

Oregon State University research has provided the first complete, cellular-level look at whats going on in joints afflicted by osteoarthritis, a debilitating and costly condition that affects nearly one-quarter of adults in the United States.

The study, published in Nature Biomedical Engineering, opens the door to better understanding how interventions such as diet, drugs and exercise affect a joints cells, which is important because cells do the work of developing, maintaining and repairing tissue.

Research by the OSU College of Engineerings Brian Bay and scientists from the Royal Veterinary College in London and University College London developed a sophisticated scanning technique to view the loaded joints of arthritic and healthy mice loaded means under strain, such as an ankle, knee or elbow would be while running, walking, throwing, etc.

Imaging techniques for quantifying changes in arthritic joints have been constrained by a number of factors, said Bay, associate professor of mechanical engineering. Restrictions on sample size and the length of scanning time are two of them, and the level of radiation used in some of the techniques ultimately damages or destroys the samples being scanned. Nanoscale resolution of intact, loaded joints had been considered unattainable.

Bay and a collaboration that also included scientists from 3Dmagination Ltd (UK), Edinburgh Napier University, the University of Manchester, the Research Complex at Harwell and the Diamond Light Source developed a way to conduct nanoscale imaging of complete bones and whole joints under precisely controlled loads.

To do that, they had to enhance resolution without compromising the field of view; reduce total radiation exposure to preserve tissue mechanics; and prevent movement during scanning.

With low-dose pink-beam synchrotron X-ray tomography, and mechanical loading with nanometric precision, we could simultaneously measure the structural organization and functional response of the tissues, Bay said. That means we can look at joints from the tissue layers down to the cellular level, with a large field of view and high resolution, without having to cut out samples.

Two features of the study make it particularly helpful in advancing the study of osteoarthritis, he said.

Using intact bones and joints means all of the functional aspects of the complex tissue layering are preserved, Bay said. And the small size of the mouse bones leads to imaging that is on the scale of the cells that develop, maintain and repair the tissues.

Osteoarthritis, the degeneration of joints, affects more than 50 million American adults, according to the Centers for Disease Control and Prevention. Women are affected at nearly a 25 percent rate, while 18 percent of men suffer from osteoarthritis.

As baby boomers continue to swell the ranks of the U.S. senior population, the prevalence of arthritis will likely increase in the coming decades, according to the CDC.

The CDC forecasts that by 2040 there will be 78 million arthritis patients, more than one-quarter of the projected total adult population; two-thirds of those with arthritis are expected to be women. Also by 2040, more than 34 million adults in the U.S. will have activity limitations due to arthritis.

Osteoarthritis will affect most of us during our lifetimes, many to the point where a knee joint or hip joint requires replacement with a costly and difficult surgery after enduring years of disability and pain, Bay said. Damage to the cartilage surfaces is associated with failure of the joint, but that damage only becomes obvious very late in the disease process, and cartilage is just the outermost layer in a complex assembly of tissues that lie deep below the surface.

Those deep tissue layers are where early changes occur as osteoarthritis develops, he said, but their basic biomechanical function and the significance of the changes are not well understood.

That has greatly hampered knowing the basic disease process and the evaluation of potential therapies to interrupt the long, uncomfortable path to joint replacement, Bay said.

Bay first demonstrated the tissue strain measurement technique 20 years ago, and it is growing in prominence as imaging has improved. Related work is being conducted for intervertebral discs and other tissues with high rates of degeneration.

This study for the first time connects measures of tissue mechanics and the arrangement of the tissues themselves at the cellular level, Bay said. This is a significant advance as methods for interrupting the osteoarthritis process will likely involve controlling cellular activity. Its a breakthrough in linking the clinical problem of joint failure with the most basic biological mechanisms involved in maintaining joint health."

The Engineering and Physical Sciences Research Council, Arthritis Research UK, the Medical Research Council, and the Diamond-Manchester Branchline at Diamond Light Source supported this research.

Continued here:
To Your Health: Study paves way to better understanding, treatment of arthritis - The Chief News

Read More...

Dingell votes in favor of legislation to drastically lower the cost of prescription drugs – Dearborn Press and Guide

December 31st, 2019 3:45 pm

U.S. Rep. Debbie Dingell (D-12th District) voted in favor of H.R. 3, the Elijah E. Cummings Lower Drugs Costs Now Act. This landmark legislation will give Medicare the power to negotiate directly with the drug companies to lower the cost of prescription drugs for Medicare beneficiaries and Michiganders with private insurance.

Too many hardworking men and women face the terrifying high costs for prescription drugs and seniors dont have coverage for dental, vision, or hearing services, said Dingell. The House is delivering on the first step to lower prescription drug prices for the people. Since coming to Congress, I have led the fight to get Medicare to cover hearing aids and service. The eyes, ears, and teeth are just as much a part of healthcare. This bill invests savings from prescription drugs right back into expanding Medicare benefits to include dental, vision, and hearing.

Making hearing aids more affordable has been a priority for Dingell since coming to Congress. The first bill she ever introduced was the Medicare Hearing Aid Coverage Act to cover hearing aids for beneficiaries. Similar legislation passed the Energy and Commerce Committee this fall.

Right now, drug prices in the US are nearly four times higher than the combined average of 11 other similar countries, and Americans pay as much as 67 times more than consumers in other nations for prescription drugs.

Through allowing Medicare to directly negotiate the cost of prescription drugs, H.R. 3 will save patients and seniors $120 billion, and reinvest have a trillion dollars in expanding Medicare benefits to cover dental, vision, and hearing services, programs to address the opioid crisis, and research for new cures and treatments.

Diabetes About 9.8 percent of Michigan 864,882 people - are living with diabetes. For the most commonly used insulin medications, Michigan residents spend anywhere from $1,200 to $20,000 annually.

Under H.R. 3, Michigan residents could spend 3.5 times less on insulin. H.R. 3 can lower the average total cost of the insulin NovoLOG Flexpen by 76% from about $19,800 to $4,800 per year. Under H.R. 3, some commonly used insulins can cost as little as $400 per year.

Arthritis - 27 percent of Michigan residents have arthritis, 30.5% of whom experience severe joint pain because of it. H.R. 3 can lower their total costs on most arthritis drugs from about $40,000 to $10,000 per year.

Asthma About 10.8 percent or 310,955 Michigan residents live with asthma. H.R. 3 can lower their total costs on most asthma drugs from about $1,400 to $270 per year.

HIV/AIDS In 2015, 777 Michigan residents were diagnosed with HIV. H.R. 3 can lower their total costs on most HIV drugs from about $15,000 to $6,000 per year.

Give Medicare the power to negotiate directly with the drug companies to bring down prices and create powerful new tools to force drug companies to the table to agree to real price reductions.

Make the lower drug prices negotiated by Medicare available to Americans with private insurance too, not just those on Medicare.

Stop drug companies ripping off Americans while charging other countries less for the same drugs by limiting the maximum price for any negotiated drug.

Create a new $2,000 out-of-pocket limit on prescription drug costs for people on Medicare.

Save taxpayers approximately $500 billion over the next ten years and reinvest that savings

Save American households $120 billion.

Save private businesses more than $40 billion.

Save taxpayers approximately $500 billion and reinvests that savings to expand benefits.

Read the original here:
Dingell votes in favor of legislation to drastically lower the cost of prescription drugs - Dearborn Press and Guide

Read More...

Vitamin D’s odd connection with pancreas inflammation – Marshall News Messenger

December 31st, 2019 3:45 pm

DEAR DR. ROACH: Are you aware of the possibility of pancreatitis resulting from long-term vitamin D2 supplementation? I was diagnosed with IPMN with chronic pancreatitis after being on 50,000 IU of vitamin D2 once a week for nine months. I had mild upper left quadrant pain, which I am told is quite unusual for pancreatic cysts. After doing some research, I decided to decrease and then stop the D2. As I did, cyst sizes and tumor markers both decreased. In addition, the pain resolved. I was fortunate enough to detect the connection, but have not had any interest from medical practitioners about looking into the possible link here. J.D.

ANSWER: This is a complex issue, and it starts with your IPMN, which stands for intraductal papillary mucinous neoplasms of the pancreas. These are tumors of the pancreas that are at risk for becoming cancerous.

The size is the biggest predictor of malignancy, so your doctors are likely monitoring the size of your tumors. Those less than 2 cm in size are at low risk for malignancy. Malignant and cancerous are synonymous terms, but the boundary between benign tumors and malignant ones is not as sharp a line as we used to think.

These cystic tumors are filled with mucin and can block the main pancreatic duct or a side pancreatic duct, through which the pancreatic enzymes that help to digest food flow into the small intestine. Insulin is also produced by the pancreas, but it is transported to the body through the splenic vein into the liver rather than the ducts into the intestine. Blockage of the ducts causes ductal dilation behind the obstruction. For the subset in whom the pancreatic ducts get blocked, IPMN can also cause inflammation of the pancreas, called pancreatitis.

Scientists observed that vitamin D levels D2 and D3, the usual kind we supplement are low in people with any kind of pancreatitis, but vitamin D treatment often made the pancreatitis worse. This seeming paradox was resolved when it was further found that the inflammatory cells in the inflamed pancreas were making the active form of vitamin D (1,25-dihydroxy vitamin D), and high levels of this active D vitamin were increasing calcium levels. The increase made pancreatitis worse. The low levels of circulating vitamin D2 and D3 are part of the bodys response to the elevated 1,25-dihydroxy vitamin D. Vitamin D supplementation is thus not usually done in pancreatitis since it can make it worse.

With the lessening of inflammation because you stopped the D2, its possible the cysts decreased in size and the ducts were able to go back toward normal, relieving inflammation in your case of IPMN.

DEAR DR. ROACH: I have just been diagnosed with a Bakers cyst behind my knee but received little information about it. Can you please tell me causes and cures? D.O.

ANSWER: A Bakers cyst is a common problem. It is a fluid collection behind the knee. In adults, these are usually due to increased joint fluid (from arthritis, a meniscal tear or trauma) communicating with the back of the knee through a one-way valve.

They are treated by addressing the underlying problem; for instance, anti-inflammatories and moderate exercise for arthritis. In addition, an injection of an anti-inflammatory into the joint space is usually successful in relieving symptoms. If a person is resistant to these treatments, an orthopedic surgeon has particular expertise in managing these.

Dr. Roach regrets that he is unable to answer individual letters, but will incorporate them in the column whenever possible. Readers may email questions to ToYourGoodHealth@med.cornell.edu or send mail to 628 Virginia Dr., Orlando, FL 32803.

Read the original:
Vitamin D's odd connection with pancreas inflammation - Marshall News Messenger

Read More...

High Uric Acid Causes Arthritis And Joint Pain Yoga For Control – By controlling uric acid, these 3 Yogasanas will relieve joint ache, common follow -…

December 31st, 2019 3:45 pm

Lifestyle Desk, , Updated Mon, 30 Dec 2019 09:27 AM IST

Uric acid is an rising drawback over time. Due to extend of this acid within the physique, an individual will get arthritis drawback. Arthritis causes swelling within the joints, inflicting insufferable ache. The impact of this ache begins displaying slowly on well being as nicely. Explain that the formation of uric acid within the physique is because of weak metabolism. Uric acid works by damaging blood cells. But yoga is one means which may eliminate this drawback. Today were telling you Three such yogasanas with the assistance of which youll management uric acid.

Abigale is a Masters in Business Administration by education. After completing her post-graduation, Abigale jumped the journalism bandwagon as a freelance journalist. Soon after that she landed a job of reporter and has been climbing the news industry ladder ever since to reach the post of editor at Our Bitcoin News.

Visit link:
High Uric Acid Causes Arthritis And Joint Pain Yoga For Control - By controlling uric acid, these 3 Yogasanas will relieve joint ache, common follow -...

Read More...

Tripterygium wilfordii Extract Market : Macroeconomic Factors to Create Positive Impact on the Industry Growth and its Potential – Market Research…

December 31st, 2019 3:45 pm

Tripterygium wilfordii, popularly known as thunder god vine root is primarily used for the treatment of rheumatoid arthritis in traditional Chinese medicine. The side effects of Trpterygium wilfordi are relatively low and hence it makes an attractive option for arthritis patients to improve their quality of life. Apart from an herbal approach in arthritis the Tripterygium wilfordii root is claimed to have antifertility, antiviral, and antitumor activities although not enough clinical evidence is available to support the claims.

This root extract is gaining significant acceptance among the arthritis patients due to its herbal nature and increasing consumers trust on herbal medicines. The regulatory aspects of herbal medicines favor the growth of herbal products market in USA, India, China and many European countries. This is expected to fuel the market growth of herbal products including Tripterygium wilfordii in the forecast period.

Tripterygium wilfordii Extract MarketSegmentation

The Tripterygium wilfordii root extract is segmented on the basis of dosage form, distribution channel and region. Tripterygium wilfordii is segmented on the bases of dosage form as tablets, capsules and powder. Originally available in powder form only, the benefits of Tripterygium wilfordii has created a costumer side demand and hence formulations of different kind have been developed and the shift in consumer trust towards herbal medicines is expected to drive the Tripterygium wilfordii market during the forecast period.

On the basis of distribution channel the Tripterygium wilfordii root extract market is segmented as retail, online retail, herbal specialty store and supermarket. With the increasing internet penetration in developing countries, the online sales of herbal supplements has also gained momentum and is expected at grow at a significant rate.

On the basis of region the Tripterygium wilfordii extract can be segmented into the following key regions; Western Europe, North America, Asia Pacific, Middle East and Africa. The Western European region, with its high expenditure on herbal medicine research is expected to drive the Tripterygium wilfordii market. The North American region has registered an ever increasing demand and acceptance in herbal products which is expected to further grow, contributing to a major factor for growth in the region. The Asia pacific region being the origin in use of Tripterygium wilfordii is also expected to see a steady increase in the market growth due to the a large populations belief in traditional remedie

Tripterygium wilfordii Extract Global Market Trends and Market Drivers:

The trends in use of traditional or herbal medicines is different for different regions, for example manufacturers do not need to register their products with FDA in US or get an approval, these are sold as dietary supplements. For this reason a large number of herbal products are flooding the American market and gaining high acceptance among masses.

The increased focus in innovation in herbal products in Western Europe is generating supply side demand and countries like Germany and France are spending high amounts on research. This is expected to act as a driving tool for the growth of the herbal product market including Tripterygium wilfordii root extract.

Request For Report Brochure for Latest Industry Insights @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=27599

In Indian regulatory system the marketing and sales of herbal products are furthermore liberal, herbal products are established products being used from a long time hence there is no safety study required for established products. This is expected to catalyze the growth of Tripterygium wilfordii root extract market.

The Tripterygium wilfordii root market is of great potential due to the above limited regulations and the high amount of faith in people for the use of herbal products. The unavailability of herbal practitioners and high concentration of the practitioners in certain regions is expected to be a major restrain in Tripterygium wilfordii root market.

Tripterygium wilfordii Extract Market Key Players:

The Tripterygium wilfordii powder from Asia Pacific constitutes for a major market share and hence some of the key prayers are also concentrated in these areas. Some of the key global players include; Shaanxi Jintai Biological Engineering Co., Ltd., Xian Hao-Xuan Bio-Tech Co., Ltd., Hunan Jin Kang Biotechnology Co., Ltd., Stanford Chemicals Co. Organic Herb Inc. among others.

This post was originally published on Market Research Sheets

Go here to read the rest:
Tripterygium wilfordii Extract Market : Macroeconomic Factors to Create Positive Impact on the Industry Growth and its Potential - Market Research...

Read More...

Safety and Efficacy of Tocilizumab as Monotherapy or in Combination with Methotrexate in Tunisian Patients with Active Rheumatoid Arthritis and…

December 31st, 2019 3:45 pm

OBJECTIVES:

We aimed to assess the safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in a routine clinical practice setting in Tunisian patients with RA who did not respond to conventional treatment with disease-modifying anti-rheumatic drugs (DMARDs-IR).

A total of 51 DMARDs-IR adult patients with moderate to severe RA participated in a phase IIIb, open-label clinical trial. Patients received 8 mg/kg of tocilizumab every 4 weeks in combination with a DMARD or as monotherapy during 24 weeks. The study was extended to 24 other weeks for those who had at least a moderate response at the end of the initial phase. Safety and efficacy of tocilizumab were analysed.

Four patients discontinued treatment prematurely due to an adverse event. The most common AEs were hypercholesterolemia (18 cases), increased triglycerides (17 cases), increased transaminases (15 cases), rash (14 cases), neutropenia (7 cases), digestive disorders (3 cases) and respiratory disorders (3 cases). After 52 weeks, 90.5% of patients responded to treatment. At the end of the study, 61.9% of the patients had a mild RA and almost 50% of patients were in remission. Overall, 29.2, 6.3 and 4.3% of patients achieved ACR20, ACR50 and ACR70 responses, respectively. Additionally, the study showed a significant improvement in all individual parameters of ACR core data.

Treatment with tocilizumab was well tolerated and showed a fast and sustained efficacy in Tunisian patients with moderate to severe active RA who had an inadequate response to DMARDs.Key Points Up to 40% of RA patients remain inadequate responders to a prior csDMARD or a tumour necrosis factor inhibitor (TNFi) biological agent. A non-TNF biological agent like tocilizumab with or without methotrexate is recommended in those patients. In this study, tocilizumab treatment improved the number of responders, the number of patients in remission, and the evolution of disease activity. The meaningful clinical improvement seen denotes a rapid and sustained response to treatment. Tocilizumab presented a favourable safety profile with few withdrawals due to AEs, consistently with what was observed in other trials. This study provides new information about the safety and efficacy of tocilizumab in a patient population resembling that expected in clinical practice among the Tunisian population.

Excerpt from:
Safety and Efficacy of Tocilizumab as Monotherapy or in Combination with Methotrexate in Tunisian Patients with Active Rheumatoid Arthritis and...

Read More...

Bar JV Angus Sale To Be Held On March 24 – The Roundup

December 31st, 2019 3:44 pm

Everyone in the Angus business brags about the Angus cow. No matter what environment you put her in she will adapt and thrive.

This year, we attended a Montana Angus Association tour of the Certified Angus Beef headquarters in Wooster, OH, and the National Angus convention, Reno, NV. We feel it is important to stay informed about changes in our industry and the quality end product we are providing to the consumer. We were especially impressed with the standards that are met with Certified Angus Beef.

Bar JV Angus has always been a family run operation. There are currently three generations collaborating at the ranch; Jim and Loretta Vitt, Dale and Jill Vitt and Cody and Sierra Vitt. We currently run 325 registered cows and 160 commercial cows. In its 44 years as a registered Angus business, Bar JV has continued to produce a product that will provide quality and increase profitability for their customers.

At Bar JV Angus we remain focused on developing a solid foundation of quality Angus genetics. Our mission is to remain focused on what is important to a commercial operation: low maintenance cows with longevity that produce pounds at weaning. Breeding elite Angus females who produce high performance bulls for the profitability of commercial cattlemen is the ultimate goal.

While the American Angus Association has provided us with a great set of selection tools, there are traits that we require beyond EPDs. Structural soundness, good feet and udders are fundamental and essential for longevity. Disposition and maternal instincts are also absolutely necessary. Also breeding bone into our cattle to enable them to handle the amount of growth that is found in today's genetics. Another thing we look for is a long neck and smooth shoulders, which ensures calving ease. We consider calving ease to be bred into our cow herd.

Dale and Jill Vitt. (Submitted photo)

They also believe that cows should be able to take care of themselves; allowing them to graze until the weather forces them to feed. In the winter season, alfalfa and grass hay are fed along with beet pulp and corn silage. Calving begins the first week of March at Bar JV, allowing most of the herd to calve out in the pasture unassisted.

Bar JV Angus' annual production sale will be held Tuesday, March 24 in the sale barn at the ranch. We will be selling 100 bulls and 180 commercial heifers. Bar JV invites you to join us on sale day. Visitors are always welcome to come by the ranch to view the bulls, heifers or the cows. We would love to show you our operation. We are always happy to discuss any questions you may have and assist in finding you the right bulls or heifers to match your needs.

The rest is here:
Bar JV Angus Sale To Be Held On March 24 - The Roundup

Read More...

Our 10 most read stories of 2019: genetics, TV, ‘Barbie Death Camp’ and more – The Jewish News of Northern California

December 31st, 2019 3:42 pm

It was quite a year for the Jews of the Bay Area. From TV shows to Barbie Death Camp to white supremacists to racial diversity in the Jewish community, here are the 10 stories our online readers clicked on the most in 2019.

It was a big year for Israeli TV in America. One show in particular, Shtisel, became an unlikely crossover hit among American viewers when the 2013-2016 series about the travails of a haredi family in Jerusalem hit Netflix late last year. As our TV reviewer Esther D. Kustanowitz wrote in January, there are some universal themes about family, community and change that kept mainstream audiences fascinated by the show:

In September, we brought you perhaps the strangest piece of news we covered this year: the curious case of Burning Mans Barbie Death Camp display. Heres how reporter Gabe Stutman described it: A sea of nude Barbies is seen moving toward three full-size kitchen ovens. Some are crucified on bright pink crosses. Other photos show toy soldiers with semi-automatic rifles marching the Barbies from the rear. A banner strapped to an RV proclaims the Barbie Death Camp the friendliest concentration camp at Burning Man. Another reads arbeit macht plastik frei, a reference to the message over the Auschwitz gate meaning work makes you free.

Some might say its the least Jewish story we wrote this year, but I beg to differ. My visit to the recently remodeled Church of Jesus Christ of Latter-day Saints Temple in Oakland was a personal highlight of the year. It was the first time it had been open to the public in over 50 years, and the visit did not disappoint. As I wrote at the time: I was there out of my love of religious architecture and because Id heard that [Mormon temples] include architectural references to the Mishkan (the portable sanctuary used by the Israelites as they wandered in the desert), as well as the ancient Temples that stood on Jerusalems Temple Mount.

No one article about him truly topped the list, but weve been covering the story since the 24-year-old Concord man was arrested in June and accused of plotting online to shoot Jews. Police found a weapons cache and Nazi literature in his home. He has been in and out of court and jail since then. Last month, a federal charge was added: In 2017, he falsified an application to join the Army by lying about his mental health history, according to the FBI. His bail has been revoked and he remains in custody as his case progresses.

This profile of iconoclastic billionaire Craig Newmark, founder of Craigslist, was the first in-depth interview he has given about his Jewish upbringing and values. More and more Im conscious of the notion of treating people like I want to be treated, and more and more Im conscious of the notion that I got lucky financially and I should share that in ways that mean something, he told our late colleague Rob Gloster in April.

The 2018 Portrait of Bay Area Jewish Life and Communities revealed that one-quarter of local Jewish households include at least one person of color. In our Jan. 25 editorial, we wrote: Its time we acknowledge not only the tendency to make Jews the other in broader society, but the equally pernicious tendency to other Jews of color right here within our own community. Our cover story is replete with stories from Jews of color being stared at or questioned when they show up in synagogue, and being passed over for leadership positions. But we also highlighted ways in which the situation is changing for the better.

Remember this years middling Netflix film The Red Sea Diving Resort, based on the secret Israeli plan to extract Ethiopian Jews through Sudan in the early 80s? Yeah, theres no reason you should. Much more interesting is the real-life story of one of the Israeli naval commandos who took part in the operation. Nir Merry lives in Mountain View today, and as he told editorial assistant Gabriel Greschler, during the operation he spent nights picking up Ethiopian Jews who had hiked for days, sometimes weeks, to reach the rendezvous point. He recalled avoiding armed Sudanese patrols on the coastline and ferrying the refugees to a disguised Israeli Navy ship in the Red Sea. We were tired but really excited, Merry said. I remember picking [up] an [Ethiopian] lady and you could hear little squeaks. And I realized it was a baby tucked in her dress close to her body.

Just last week, Adam Eilath, head of school at Ronald C. Wornick Jewish Day School in Foster City, registered his dismay at the Hanukkah-themed episode of the Disney series Elena of Avalor. In his opinion piece he wrote, As a Sephardic Jew raising two small daughters in an American Jewish community whose default is almost always Ashkenazi. I was excited that the episode would feature Princess Rebekah from a Latino (Ladino) Jewish kingdom. But, he continued, As usual, the only way that Sephardic culture gets represented in this episode is by incorporating Sephardic food.

This story was part of a three-part series on the rise of home genetic testing and the ease of doing genealogical research from the comfort of your home computer. One woman we spoke with grew up Catholic, but found out that she was 50% Asheknazi Jewish from a 23andMe home genetic test. But, as reporter Maya Mirsky asks, what does that really mean? The question itself is a new wrinkle in the age-old debate of just what it means to be Jewish, which has been given a kick in the pants from the commercialization of a field of science that says it can tell you something new: For a price, you can now choose from one of seven commercial genetic tests to find out just how Jewish you are.

In October we reported on a Nazi flag seen hanging inside a state parole office in Sacramento. How did it get there? And why was it hanging in a government building? The California Department of Corrections and Rehabilitation told us in an email that they have a zero tolerance policy for the display of objects that are derogatory in nature, but they pointed out that their officers deal with gang members and high-risk sex offenders, [so] we will come into contact with items that may be considered objectionable. However, the email continued, We take this issue seriously and have removed the item and are looking into the circumstances for why the flag was displayed in potential view of the public. No word yet on what they found out.

View post:
Our 10 most read stories of 2019: genetics, TV, 'Barbie Death Camp' and more - The Jewish News of Northern California

Read More...

Page 743«..1020..742743744745..750760..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick